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Abstract 
Endonuclease G (EndoG) is a well conserved mitochondrial nuclease with dual lethal and 
vital roles in the cell. It non-specifically cleaves endogenous DNA following apoptosis 
induction, but is also active in non-apoptotic cells for mitochondrial DNA (mtDNA) 
replication and may also be important for replication, repair and recombination of 
genomic DNA. The aim of our study was to examine whether EndoG exerts similar 
activities on exogenous DNA substrates such as plasmid DNA (pDNA) and viral DNA 
vectors, considering their importance in gene therapy applications. The effects of EndoG 
knockdown on pDNA stability and levels of encoded reporter gene expression were 
evaluated in the cervical carcinoma HeLa cells. Transfection of pDNA vectors encoding 
short-hairpin RNAs (shRNAs) reduced levels of EndoG mRNA and nuclease activity in 
HeLa cells. In physiological circumstances, EndoG knockdown did not have an effect on 
the stability of pDNA or the levels of encoded transgene expression as measured over a 
four day time-course. However, when endogenous expression of EndoG was induced by 
an extrinsic stimulus (a cationic liposome transfection reagent), targeting of EndoG by 
shRNA improved the perceived stability and transgene expression of pDNA vectors. 
Therefore, EndoG is not a mediator of exogenous DNA clearance, but in non-
physiological circumstances it may non-specifically cleave intracellular DNA regardless 
of its origin. To investigate possible effects of EndoG on viral DNA vectors, we 
constructed and evaluated AdsiEndoG, a first generation adenovirus (Ad5 ΔE1) vector 
encoding a shRNA directed against EndoG mRNA, along with appropriate Ad5 ΔE1 
controls. Infection of HeLa cells with AdsiEndoG at a multiplicity of infection (MOI) of 
10 p.f.u./cell resulted in an early cell proliferation defect, absent from cells infected at 
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equivalent MOI with control Ad5 ΔE1 vectors. Replication of Ad5 ΔE1 DNA was 
detected for all vectors, but AdsiEndoG DNA accumulated to levels that were 50 fold 
higher than initially, four days after infection, compared to 14 fold for the next highest 
control Ad5 ΔE1 vector. Deregulation of the cell cycle by EndoG depletion, which is 
characterized by an accumulation of cells in the G2/M transition, is the most likely reason 
for the observed cell proliferation defect. The enhanced replication of AdsiEndoG is 
consistent with this conclusion, as Ad5 ΔE1 DNA replication is intimately related to cell 
cycling and prolongation or delay in G2/M greatly enhances this process. Furthermore, 
infection of HeLa with AdsiEndoG at MOI of 50 p.f.u./cell resulted in an almost 
complete disappearance of viable, adherent tumour cells from culture, whereas almost a 
third of the cells were still adherent after infection with control Ad5 ΔE1 vectors, relative 
to the non-infected control. Therefore, targeting of EndoG by RNAi is a viable strategy 
for improving the oncolytic properties of first generation adenovirus vectors. In addition, 
AdsiEndoG-mediated knockdown of EndoG reduced homologous recombination between 
pDNA substrates in HeLa cells. The effect was modest but, nevertheless demonstrated 
that the proposed role of EndoG in homologous recombination of cellular DNA also 
extends to exogenous DNA substrates.  
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General Introduction and Aim of the Study 
The human genome encodes multiple deoxyribonucleases (DNases), yet they all function 
to hydrolyze the phosphodiester bond on a single substrate: DNA. From an evolutionary 
perspective, the question that presents itself is: Why does our genome encode so many 
different enzymes that have overlapping activities? Although genetic redundancy cannot 
be discounted, it appears that the answer may lie in the diverse biological roles these 
enzymes perform, or in which they are speculated to participate. Below is a brief review 
of the major human DNases that outline this diversity of functions, which is well 
highlighted in the case of the conserved and ubiquitously expressed mitochondrial 
endonuclease G (EndoG).  
Caspase activated deoxyribonuclease  
Caspase activated deoxyribonuclease (CAD) is the “professional” apoptotic endonuclease 
in human cells (reviewed in Baranovskii et al., 2004 and Samejima and Earnshaw, 2005). 
It non-specifically cleaves endogenous chromatin substrates during the last stages of 
apoptosis, after the cell has already committed to death (Enari et al., 1998). Unlike many 
other apoptotic proteins, activity of CAD is restricted exclusively to apoptosis and it has 
no known functions in physiological circumstances (reviewed in Samejima and 
Earnshaw, 2005). Tight regulation of CAD activity in the cells is facilitated by an 
inhibitor of CAD (ICAD) protein that is normally always bound to CAD to prevent 
formation of functional CAD homodimers (Korn et al., 2005). Apart from acting as an 
inhibitor of CAD, ICAD is also a protein chaperone that is required for proper CAD 
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folding (Enari et al., 1998). Therefore, ICAD regulates CAD at the level of protein 
expression, as well as enzymatic activity.  
The CAD/ICAD protein complex is normally localized in the nucleus along with an 
excess of free ICAD proteins that serve as a failsafe against accidental CAD activation 
(Samejima and Earnshaw, 1998; Widlak et al., 2003). When apoptosis is induced through 
the death receptors, proteolytic activities of caspases 3 and 7 facilitate the release of CAD 
from ICAD, which subsequently leads to the assembly of enzymatically active CAD 
homodimers (Widlak et al., 2003; Woo et al., 2004). Active CAD cleaves the chromatin 
at internucleosomal regions to produce the characteristic laddering of DNA when 
visualized on an agarose gel, which is a hallmark event in programmed cell death 
(reviewed in Samejima and Earnshaw, 2005).  
Deoxyribonuclease I  
Deoxyribonuclease I (DNase I) is a neutral Mg2+/Ca2+ dependent endonuclease mainly 
expressed in the pancreas (Shiokawa and Tanuma, 2001). It is the major secretory 
endonuclease, as evidenced by a hydrophobic signal peptide at its amino terminus and a 
high glycosylation level. In the cell, DNase I is found in the rough endoplasmic 
reticulum, Golgi apparatus and secretory granules, which corresponds to the traditional 
secretory route (reviewed in Baranovskii et al., 2004). Neutral DNase activity matching 
DNase I catalytic properties can be detected at low levels in the circulation and at higher 
levels in urine (Nadano et al., 1993). 
Due to its presence in blood, DNase I is perceived as a “waste management” nuclease 
that prevents accumulation of DNA in the circulation (reviewed in Baranovskii et al., 
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2004 and Samejima and Earnshaw, 2005). As such, downregulation of DNase I activity 
has been correlated with development of the autoimmune disorder, systemic lupus 
erythematosus, which is characterized by an inappropriate immune response to DNA 
auto-antigens (reviewed in Martinez Valle et al., 2008).  
Deoxyribonuclease II 
Deoxyribonuclease II (DNase II) is an acid hydrolase with a pH optimum of 4.8-5.2 that 
has a lysosomal cellular localization (Baker et al., 1998). It activity is reduced by a 100 
fold at neutral pH compared to optimum. The compartmentalization of DNase II in the 
lysosome, coupled with its requirement for an acidic environment and the fact that its 
catalytic activity leaves a 3`-terminal phosphate make it unlikely that it participates in 
DNA replication, repair and recombination (reviewed in Baranovskii et al., 2004).  
DNase II has been suggested to participate in cell-autonomous DNA degradation during 
apoptosis, but this role has not been definitively established (Nakagami et al., 2003; 
reviewed in Baranovskii et al., 2004). The primary role of DNase II is in engulfment-
mediated degradation of DNA (McIlroy et al., 2000; reviewed in Samejima and 
Earnshaw, 2005). Therefore, macrophages depend on the action of DNase II for 
catabolism of DNA found in engulfed apoptotic bodies and also DNA of engulfed 
pathogens (reviewed in Evans et al., 2003; Krieser et al., 2002). 
Deoxyribonuclease gamma 
Deoxyribonuclease gamma (DNase γ) belongs to DNase I-like nucleases as it is closely 
related to DNase I based on sequence homology and catalytic activity (reviwed in 
Baranovskii et al., 2004). It is mainly expressed in macrophages, liver and spleen, but can 
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be found in other organs (Baron et al., 1998). Although some authors have argued that 
DNase γ is secreted into the extracellular space, others have localized this enzyme in the 
perinuclear space (Baron et al., 1998; Shiokawa and Tanuma, 2001). In addition, the 
polypeptide chain of DNase γ contains two nuclear localization signals, suggesting that it 
may participate in the degradation of chromatin following the induction of apoptosis 
(Shiokawa et al., 2002). Furthermore, studies of neuronal apoptosis showed that DNase γ 
replaces CAD as the primary low molecular weight DNA degradation nuclease based on 
the differentiation of the cells (Shiokawa and Tanuma, 2004). 
Endonuclease G 
Endonuclease G (EndoG) is encoded on nuclear DNA, but its primary cellular 
localization is in the intermembrane space of mitochondria (Diener et al., 2010). Its 
cellular location suggested a role in mitochondrial DNA (mtDNA) replication, however, 
some controversy arose after initial studies on EndoG knockout mice failed to 
demonstrate any mtDNA-associated phenotypes (Ohsato et al., 2002; David et al., 2006). 
Subsequently, EndoG has been shown to be an apoptosis regulator that responds to 
intrinsic and extrinsic stimuli that compromise the mitochondrial membrane potential and 
facilitate its release from the intermembrane space (Li et al., 2001). Translocation of 
EndoG from its cellular compartment to the nucleus coincides with high scale genomic 
DNA degradation and commits the cell to death. Although other nucleases with more 
defined roles in apoptosis have been discovered, of which the caspase activated DNase 
(CAD) is the most specialized for this function, EndoG is thought to be important for 
responding to cell-death stimuli which bypass caspase activation (Arnoult et al., 2003; 
Bahi et al., 2006; Strauss et al., 2008). 
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Apart from its pro-death role, EndoG has been shown to have a dual vital role in the cell 
which is centered on the maintenance of both mitochondrial and nuclear DNA 
(McDermott et al., 2011; Huang et al., 2006). As mentioned previously initial studies on 
EndoG knockout mice did not demonstrate any readily observable phenotypes on mtDNA 
synthesis, however, a recent study by McDermott et al. (2011), showed a physical 
interaction of EndoG with mtDNA and furthermore, discovered that EndoG knockout 
mice do, in fact, display a mtDNA synthesis defect that leads to an increase in the left-
ventricular mass of the heart.  
The presence of EndoG in nuclei of viable, non-apoptotic cells, suggested that its 
function is not restricted exclusively to mtDNA and apoptotic DNA degradation (Côté 
and Ruiz-Carrillo, 1993; Ikeda et al., 1997; Huang et al., 2002; Huang et al., 2006; 
Buttner et al., 2007b; Zan et al., 2011). Circumstantial evidence for the role of EndoG in 
the maintenance of nuclear DNA has come from observations that EndoG has an affinity 
for sites of DNA damage and that it co-immunoprecipitates with enzymes with 
established roles in genome stability and mutation sensitivity (Ikeda and Ozaki, 1997; 
Guo et al., 2008). In addition, EndoG is a cell cycle regulator in physiological 
circumstances and its depletion from cultured cells results in a proliferation defect, 
characterized by an accumulation of cells in the G2/M transition, which is consistent with 
an increase in unrepaired DNA damage (Huang et al, 2006; Buttner et al., 2007a,b; 
reviewed in Galluzzi et al., 2012). Therefore, EndoG may participate in the processes of 
cellular DNA repair and/or replication. 
EndoG has also been shown to participate in homologous recombination. Specifically, it 
cleaves the alpha (α) sequence in the genome of herpes simplex type I (HSV I) virus, 
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which is an initial event in viral genome isomerization (Huang et al., 2002; Huang et al., 
2006). Similarly, EndoG induces double stranded breaks in switch regions of 
immunoglobulin genes, resulting in class switch DNA recombination in mouse B cells 
(Zan et al., 2011). Furthermore, EndoG depletion results in nearly complete eradication 
of polyploidy in mammalian and yeast cell cultures (Diener et al., 2010; Buttner et al., 
2007a). Maintenance of polyploidy is much more dependent on efficient homologous 
recombination, relative to haploid or diploid phenotypes, suggesting that EndoG is 
involved in this process. 
Taking all of the above into consideration, it is clear that the proposed biological roles of 
EndoG are extremely varied, as exemplified by the fact they extend into both pro-death 
and vital cellular functions. However, the one thing they have in common is the 
requirement for the enzyme to exert its nuclease activity on endogenous DNA substrates. 
The question that presents itself is whether EndoG also interacts with exogenous DNA 
and if it does, what are the consequences of that interaction? 
EndoG has already been implicated as a cellular defence enzyme by Buzder et al., (2009) 
who demonstrated improved transfection efficiency of cultured mouse cells upon EndoG 
depletion. It is unknown whether this extends to other mammalian cells and tissues, but 
would be important to investigate considering the importance of efficient transgene 
delivery in gene therapy applications. In addition to foreign DNA (fDNA) uptake, 
proposed biological roles of EndoG also lend themselves for speculation about other 
possible effects on exogenous DNA substrates, including its effects on exogenous DNA 
intranuclear stability, expression of encoded genes, replication and recombination.  
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Therefore the aim of this study was to investigate the biological role of EndoG on: 
1. Plasmid DNA (pDNA) stability and gene expression,  
2. Adenovirus vector replication, and 
3. pDNA uptake and recombination efficiency. 
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Chapter I 
 
EndoG silencing does not increase stability of exogenous DNA in HeLa 
cells 
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1.1 Introduction 
 
Endonuclease G (EndoG) is a member of the conserved DNA/RNA nonspecific ββα-
metal-ion-finger nuclease family (Diener et al., 2010). It was first isolated from calf 
thymus, but homologues have been described in many model organisms such as 
Caenorhabditis elegans (Parrish et al., 2001), Mus musculus (Li et al., 2001), 
Saccharomyces cerevisiae (Buttner et al., 2007b) and importantly in humans (Kieper et 
al., 2010). It is a nuclear encoded mitochondrial enzyme, which is translated as a 33 kDa 
preprotein with a mitochondria localization signal (MLS) and further processed by 
cleavage to a 28 kDa mature protein upon translocation into the mitochondrial 
intermembrane space (Diener et al., 2010). EndoG exerts its nuclease activity on double 
and single stranded DNA, RNA and DNA/RNA heteroduplexes. EndoG derives its name 
from the observed preference of the enzyme to first attack (dG)n.(dC)n tracts of double 
stranded DNA (dsDNA) by introducing single stranded breaks in its substrate, however, 
it is able to catalyze phosphodiesters in a non-specific fashion (Widlak et al., 2001). It is 
dependent on Mn2+ or Mg2+ (but not Ca2+) as its divalent cation and shows much 
greater activity on single stranded nucleic acid substrates (like ssDNA and RNA) than 
dsDNA (Widlak et al., 2001). EndoG is characterized as a nickase, an enzyme that 
introduces “nicks” (or single stranded breaks) in dsDNA, as illustrated by first-hit 
kinetics analysis, which shows that supercoiled plasmids are first relaxed by this action of 
the enzyme (Widlak et al., 2001). The substrate becomes completely degraded when 
nicks accumulate on opposite strands of the dsDNA, resulting in double stranded breaks. 
For catalysis, the conserved residues His143, Asn174, and Glu182 are important for 
metal binding and Arg141 for substrate binding (Schafer et al., 2004). 
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1.1.1 Biological functions of EndoG 
Although biochemical studies have answered how EndoG acts on its substrates, the 
question that still remains unanswered is: What is the biological function of EndoG? 
Initially it was thought that EndoG participates in mitochondrial DNA (mtDNA) 
replication for primer generation, but that view generated some controversy, partly 
because EndoG was not readily detected in the matrix where replication occurs and 
because EndoG homozygous knockout mice did not show obvious defects in this process 
(Ohsato et al., 2002; David et al., 2006). However, a recent study by McDermott et al. 
(2011) showed a physical interaction of EndoG with mtDNA and furthermore, discovered 
that EndoG knockout mice do, in fact, display a mtDNA synthesis defect that leads to an 
increase in the left-ventricular mass of the heart.  
EndoG has mostly been investigated in the context of programmed cell death as one of 
the executioners of apoptotic degradation of genomic DNA (Strauss et al., 2008). In this 
function, EndoG has been shown to translocate from the mitochondrial intermembrane 
space to the nucleus in response to various apoptotic stimuli that compromise the function 
of mitochondria (Li et al., 2001). There is still some uncertainty whether the apoptotic 
function of EndoG is dependent on caspase activation or if it is caspase independent, 
however, recent studies have skewed the opinion towards the latter (Arnoult et al., 2003; 
Bahi et al., 2006; Strauss et al., 2008). Once in the nucleus, it exerts its nuclease activity 
on the chromatin and results in genomic DNA laddering, which is a hallmark event in 
end-stage apoptosis.  
25 
 
The pro-death role of EndoG appears to depend greatly on its expression level in the cell 
(Wang et al., 2008; Basnakian et al., 2006). Cell lines of aggressive prostate and breast 
cancer, which display reduced EndoG expression, due to CpG methylation of EndoG 
promoter/exon1, are more resistant to chemotherapeutic agents such as cisplatin and 
etoposide (Wang et al., 2008; Basnakian et al., 2006). Furthermore, depletion of cellular 
EndoG by RNA interference (RNAi) makes previously sensitive cells become much more 
resistant to these apoptosis inducers, highlighting the central role of EndoG-mediated 
chromatin degradation in cell fate commitment to death.  
Although constitutively expressed, EndoG expression can be transcriptionally induced 
during times of cellular stress and its responsiveness to various exogenous stimuli such as 
ischemia/reoxygenation, reactive oxygen species (ROS) or oxygen-glucose deprivation 
and apoptotic inducers such as cisplatin, curcumin, berberine or gallic acid has been 
observed (Li et al., 2004; Zhao et al., 2009; Zhang et al., 2009; Lee et al., 2008; Mercer et 
al., 2010; Papa and Germain, 2011; Apostolov et al., 2011; Wu et al., 2010; Mitra et al., 
2012; Ho et al., 2009; Yeh et al., 2011). The increase in cellular levels of EndoG shortly 
precedes the onset of apoptotic cell death, characterized by chromatin condensation and 
degradation.  
1.1.2 Evidence for a vital role of EndoG 
Apart from its pro-death role in programmed cell death, EndoG has been implicated as 
having vital functions in the cell, which merit further investigation. Namely EndoG has 
been linked to DNA repair, recombination and/or replication and also as an enzyme 
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involved in cellular defence against foreign nucleic acids (Huang et al, 2002; Huang et al, 
2006; Buttner et al., 2007a,b; Buzder et al., 2009; Zan et al., 2011).  
EndoG was first identified in nuclei of cells that were not undergoing apoptosis (Côté and 
Ruiz-Carrillo, 1993; Gerschenson et al., 1995). Nuclear localization of EndoG in healthy 
cells is important in the context of its proposed vital functions in DNA repair, 
recombination and/or replication. First evidence for a role of this enzyme in DNA repair 
comes from in vitro assays that showed EndoG has strong affinity for sites of oxidative 
damage or sites distorted by DNA crosslinking agents (Ikeda and Ozaki, 1997). 
Specifically, susceptibility of DNA to nucleolytic attacks by EndoG is greatly enhanced 
after treatments with L-ascorbic acid or peplomycin, which introduce single-stranded 
breaks in the substrate via active oxygen radicals, with EndoG cleaving the substrate at or 
near these sites in the opposite strand. In addition, EndoG recognized and cleaved at sites 
of DNA distortions caused by cis-diamminedichloroplatinum(II), which induces 
intrastrand crosslinking. Further, EndoG may act with other co-factors in DNA repair as 
was suggested by findings that it immunoprecipitates with flap endonuclease 1 (FEN-1), 
an enzyme that is involved in long-patch base excision repair (Guo et al., 2008).  
Involvement of EndoG in recombination was first reported by Huang et al. (2002), who 
showed that it was the only enzyme isolated from HeLa cell nuclei that was able to cleave 
the herpes simplex virus 1 (HSV-1) α sequence and thereby initiate the recombinational 
event that is responsible for HSV-1 genome inversion. A follow-up study by the same 
group also showed that a knockdown of EndoG in Vero cells resulted in a decrease of 
HSV-1 α sequence recombination, further implicating EndoG in this process (Huang et 
al, 2006). Recently, EndoG has been identified as one of the enzymes involved in 
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immunoglobulin class switch DNA recombination (CSR) in mouse B cells (Zan et al., 
2011). The action of EndoG to induce dsDNA breaks in switch regions of the upstream 
and downstream CH genes is required for efficient CSR, as it was shown that this process 
is decreased by two-fold in B cells of EndoG null mice. It is important to note that the 
lowered efficiency of CSR in EndoG null mice was not related to any changes in B cell 
apoptosis. 
Indirect evidence of EndoG involvement in homologous recombination comes from 
observations that decreased or attenuated expression of this enzyme results in near 
complete elimination of polyploidy in both yeasts and mammalian cells (Diener et al., 
2010; Buttner et al., 2007a). Polyploidization is associated with genomic instability and is 
recognized as a precursor to aneuploidy in cancer (Buttner et al., 2007a). Survival of 
polyploidy cells is much more dependent on homologous recombination than that of 
diploid or haploid cells, as has been demonstrated by screening knockouts of genes 
involved in this process. Interestingly, deletion of NUC1, the yeast EndoG homologue 
(42% identity, 62% similarity), decreases the abundance of the polyploid phenotype from 
a starting 20% of the growing yeast population to less than 1% (Buttner et al., 2007a). 
Similarly, EndoG knockdown in both human endothelial cells and human colon cancer 
cell lines results in specific killing of tetraploid cells (Diener et al., 2010; Buttner et al., 
2007a). These observations imply that EndoG participates in genome maintenance by 
homologous recombination, however, there is not enough evidence currently for a 
definitive call. 
EndoG also appears to be important for cellular proliferation in both yeasts and 
mammalian cells (Buttner et al., 2007b; Huang et al, 2006). EndoG deletion in yeasts 
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growing on fermentable media sensitizes cells to cell death by apoptotic stimuli like 
hydrogen peroxide and, importantly, leads to a significant decrease in cell survival even 
in the absence of these stimuli (Buttner et al., 2007b). Exogenous expression of EndoG at 
low levels can rescue this phenotype, but only if the enzyme retains its nuclease activity. 
Reduction of proliferation by EndoG depletion is characterized by an increase of cells in 
the G2/M phase of the cell cycle, suggesting a delay in G2/M (Buttner et al., 2007a,b). 
Similarly, knockdown of EndoG in human endothelial, colon cancer, Vero and 293T cells 
results in a decrease in cellular proliferation (Diener et al., 2010; Huang et al, 2006; 
Buttner et al., 2007a). These cells also become arrested in the G2/M phase of the cell 
cycle (Huang et al, 2006). Exogenous expression of EndoG as a fusion protein with GFP 
is able to reverse the phenotype (Huang et al, 2006). Because EndoG compromised yeast 
and mammalian cells become arrested in the G2/M phase of the cell cycle, which is 
consistent with an accumulation of damaged DNA, EndoG could function in DNA repair, 
recombination and/or replication (Huang et al, 2006; Buttner et al., 2007a). Additionally, 
despite EndoG’s characterization as a pro-apoptotic factor, its expression is elevated in 
colorectal and gastric carcinomas (relative to normal mucosal cells of these tissues), also 
suggesting a pro-life role for the enzyme.  
1.1.3 A role for EndoG in cellular defence against foreign nucleic acids 
Uptake of exogenous DNA occurs during normal tissue growth, tumour growth, viral and 
bacterial infections, and as a result of intentional genetic manipulations in experimental 
animals and cultured cells (Buzder et al., 2009). It is also the core principle of gene 
therapy applications, where efficient delivery of exogenous DNA is required for 
sustained expression of therapeutic genes in target cells and tissues (Ochiai et al., 2006a). 
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However, intracellular double stranded DNA fragments (from infectious agents or 
transfection experiments) trigger innate antiviral immune responses via a signaling 
pathway that involves extrachromosomal histone H2B (Kobiyama et al., 2010). Further, it 
has been experimentally demonstrated that entry of exogenous DNA is harmful to the 
host cell and that it can trigger p53-dependent apoptotic cell death (Li et al., 1999; Nur et 
al., 2003). Another detrimental effect of exogenous DNA is the possibility for insertional 
mutagenesis due to homologous or non-homologous recombination (Torchilin, 2006). 
Therefore, the cell depends on an active mechanism to restrict DNA uptake and attenuate 
these deleterious effects (Buzder et al., 2009). Unfortunately, the activity of this defence 
mechanism also presents a barrier for intentional genetic manipulations and is an 
impediment to successful gene therapy applications.  
Keeping in mind that entry of exogenous DNA into the host cell is followed in large part 
by its degradation (even when protected by lipid or viral packaging), the main effectors of 
this defence mechanism must be DNA degrading enzymes (Buzder et al., 2009). The first 
line of defence against exogenous DNA is in the cytosol, where, as of yet, unidentified 
DNases actively reduce the amount of DNA available for entry into the nucleus. This 
effect occurs within 50-90 minutes following microinjection of naked DNA into the 
cytoplasm or after it is released from endosomes following transfection with cationic 
lipids (Chu et al., 2006). Although cytosolic degradation of exogenous DNA is a major 
hurdle for successful gene delivery, it is not the only barrier for efficient and prolonged 
gene expression, as intranuclear disposition of non-integrating vectors, following DNA 
entry into the nucleus, is also a key factor (Ochiai et al., 2006a).      
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Silencing of genes encoded on non-integrating exogenous DNA, such as pDNA, has been 
observed in vitro and in vivo, resulting in the reduction of both the level and the duration 
of transient transgene expression (Chu et al., 2006; Ochiai et al., 2006a; Yamada et al., 
2005; Berraondo et al., 2009; Ochiai et al., 2006b). Accordingly, highest levels of 
transient transgene expression in mammalian cells from non-viral plasmid vectors are 
observed early after pDNA delivery (24-48 hours) and dissipate shortly thereafter (72 
hours). Transgene expression decreases over time with respect to plasmid copy number, 
suggesting that transgene copies are inactivated even after nuclear entry (Chu et al., 2006; 
Ochiai et al., 2006a; Yamada et al., 2005; Berraondo et al., 2009; Ochiai et al., 2006b). 
Part of the observed phenomenon may be attributed to de novo CpG methylation of 
exogenous DNA and/or deactivation by modification of DNA bound histones in addition 
to chromatin remodeling events. However, there is increasing evidence which suggests 
that much of the silencing occurs as a result of intranuclear exogenous DNA degradation, 
which occurs in parallel to other silencing mechanisms (Chu et al., 2006; Ochiai et al., 
2006a; Yamada et al., 2005; Berraondo et al., 2009; Ochiai et al., 2006b). It is still 
unclear whether pDNA degradation is a specific action aimed at exogenous DNA 
clearance, or a byproduct of endogenous nuclease activities required for normal cellular 
DNA replication, recombination and repair, which are abundantly present in mammalian 
nuclei (Ochiai et al., 2006a).     
Since EndoG has indirectly been implicated in DNA replication/repair and 
recombination, all of which would require its nuclease action in the nuclei of healthy, 
non-apoptotic, cells, a valid hypothesis is that it may be involved in intranuclear 
disposition of exogenous DNA, whether as consequence of non-specific action on DNA 
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substrates or a specific defence role. EndoG has already been implicated as a defence 
nuclease in experiments in primary tubular epithelial (PTE) cells of EndoG null mice. 
Transfection efficiency of EndoG null mouse PTE cells is more than two-fold higher than 
that of wildtype control PTE cells, as measured by a fluorescence reporter assay 
(facilitated by expression of CFP from the transfected plasmid) (Buzder et al., 2009).  
Although the above finding argues that EndoG presents a block to transfection in its 
suggested defence role, it fails to explain how an enzyme with a nuclear/mitochondrial 
localization and not cytoplasmic could effectively prevent plasmid DNA (pDNA) from 
entering the nucleus. In addition, the effect of EndoG knockout on transgene expression 
was more pronounced at 48 than at 24 hours post transfection, and transfection efficiency 
was not assayed by pDNA copy number, but rather by transgene expression (Buzder et 
al., 2009). This opens up the possibility that EndoG may have degraded pDNA in the 
nucleus over time, rather than in the cytoplasm to prevent its entry.  
Therefore the aim of our study was to investigate whether EndoG is a defence enzyme 
involved in intranuclear disposition of exogenous DNA in replicating mammalian cells. 
The hypothesis was that EndoG targeting by RNAi would augment pDNA stability and 
transgene expression in the cervical carcinoma HeLa cells. Our experimental approach 
was to compare the stability of pDNA and encoded transgene expression, with respect to 
time, between pDNA that could facilitate a knockdown of EndoG and control pDNA in 
HeLa cells. For this purpose, we engineered a short-hairpin RNA (shRNA) expression 
pDNA vector, pDC-CG-U6, and armed it with templates for the expression of shRNAs 
targeting six unique regions of EndoG mRNA. In addition to these six pDNA vectors, we 
constructed a negative control vector based on the same backbone but encoding a non-
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targeting shRNA. These vectors were independently transfected into HeLa cells and their 
cellular levels as well as the expression of an encoded transgene were monitored over a 
four day time course at 24 hour intervals. By design, we avoided transfection of pDNA 
into HeLa cells that had differential EndoG levels at outset of experiment because of the 
previously reported effect of EndoG on pDNA uptake (Buzder et al., 2009). 
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1.2 Materials and Methods 
1.2.1 Selection of targets within EndoG mRNA 
Invitrogen’s BLOCK-iT™ RNAi Designer tool (http://rnaidesigner.invitrogen.com/ 
rnaiexpress/) was used to identify suitable regions within EndoG mRNA for targeting by 
shRNAs. In step 1, full length EndoG mRNA was used as input. In step 2, targeting was 
limited to the open reading frame (ORF) of the gene. In step 3, BLAST was used to filter 
targeting to sequences which are unique to EndoG mRNA using the Human – Homo 
sapiens database for reference (May 1, 2008 update). In step 4, default settings were used 
for target G/C content, minimum 35% and maximum 55%. In step 5, unique regions 
within EndoG mRNA, suitable for RNAi targeting, were identified (Table 1.1). 
Table 1.1 - Sequences within the EndoG mRNA chosen for targeting by RNAi. 
Start position of target seq. on EndoG mRNA (nt) Target sequence (5`- 3`) 
644 GGCCAUGGACGACACGUUCUA 
653 CGACACGUUCUACCUGAGCAA 
704 GAAUGCCUGGAACAACCUGGA 
805 CTGAUGGGAAAUCCUACGUAA 
809 UGGGAAAUCCUACGUAAAGUA 
1009 GGCUGCUCUUUGUGCCAAACA 
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1.2.2 Construction of pDC-CG-U6, a shRNA expression vector 
To express shRNAs directed against EndoG mRNA we constructed the plasmid vector 
pDC-CG-U6. The pDC-CG shuttle vector contained a GFP expression cassette under the 
control of the cytomegalovirus immediate/early (CMVie) promoter/enhancer and a small 
multi-cloning site (MCS) upstream of the cassette. We cloned the RNA Pol III promoter 
U6 at the Eco RI restriction site, while preserving the downstream MCS for insertion of 
shRNA DNA templates. Therefore, pDC-CG-U6 contained two adjacent transgene 
expression cassettes in the same orientation, one of which was used to express shRNA, 
driven by the U6 promoter, and the other to express green fluorescent protein (GFP), 
driven by the CMVie promoter/enhancer. The U6 promoter was chosen for shRNA 
expression because it regulates expression of small RNAs in its endogenous context and 
also because it requires a very short transcription termination signal (stretch of 4-6 T 
nucleotides). The cloning steps in the construction of pDC-CG-U6 are outlined below. 
The RNA Pol III promoter U6 was amplified by PCR using Pfu DNA Pol, which has 
proofreading ability, using the pSilencer 2.1-U6 neo vector as a template (Ambion). 
Primers used for PCR were: U6 F: 5`AGCATGCAATTGCCCCCAGTGGAAAGACG3` 
and U6 R: 5`CGAATTCGGATCCCGCGTCCTTTCC3`. The forward primer had a 5` 
flanking sequence corresponding to the recognition site of Mfe I restriction enzyme and 
the reverse primer had a 5` flanking sequence corresponding to the recognition sequence 
of Eco RI restriction enzyme, which were not in the template sequence, but were required 
for downstream cloning. The PCR amplicon of U6 was cleaned and concentrated using a 
commercially available kit (PCR Purification Kit, Norgen Biotek).  
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In the next step, the U6 promoter, flanked by sequences of Mfe I and Eco RI recognition 
sites (5` to 3`), was ligated into a pUC19 vector previously digested with restriction 
enzyme Hinc II, which produced blunt ends. This step was necessary before cloning into 
pDC-CG due to the severely reduced activity of Mfe I on PCR products. The resultant 
vector, pUC19-U6 was amplified in Escherichia coli (E. coli) DH5α and purified by a 
commercial pDNA isolation kit (Plasmid MiniPrep DNA Kit, Norgen Biotek). 
Subsequently, the pUC19-U6 was digested with Mfe I and Eco RI restriction 
endonucleases and agarose gel electrophoresis was used to separate the U6 fragment from 
the pUC19 backbone. The band corresponding to U6 was excised from the agarose gel 
and purified using a commercially available kit (DNA Gel Extraction Kit, Norgen 
Biotek). 
The shuttle vector pDC-CG was digested by Eco RI and the purified U6 promoter was 
incorporated into the vector by the T4 DNA ligase reaction (New England Biolabs). The 
sticky ends generated by Mfe I and Eco RI are compatible, but when annealed they 
produce a sequence that cannot be cleaved by either of the enzymes. Therefore the 
uniqueness of the Eco RI recognition site was preserved in pDC-CG-U6, directly 
downstream of the U6 promoter, which was important for subsequent insertions of 
various shRNA DNA templates. 
1.2.3 Confirmation of sequence fidelity of pDC-CG-U6 
The U6 promoter insert had the potential to form concatemers and also to ligate in either 
orientation into the pDC-CG shuttle vector, due to the compatibility of its sticky ends, 
making identification of E. coli DH5α clones harboring the correct version of pDC-CG-
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U6 extremely tedious by conventional methods. To make the process more efficient, we 
screened bacterial colonies by an end-point PCR protocol that was sensitive as well as 
specific. Each bacterial colony that was screened was first resuspended in 20 µL of water, 
2 µL of which was used as a template for PCR without prior DNA isolation.  
The primers used in the PCR were F: 5`AGCATGCAATTGCCCCCAGTGGAAAG-
ACG3` and R: 5`GATGTTGCCATCCTCCTTGA3`. The forward primer annealed to a 
region within the U6 promoter and the reverse primer annealed to a sequence in the pDC-
CG backbone and only a single U6 insert in the proper orientation yielded a 1660bp 
amplicon. Of the 94 colonies screened by this method, only one clone, number 46, 
produced this specific amplicon after agarose gel electrophoresis of the PCR products. 
This clone was grown in ampicillin supplemented Luria- Bertani (LB) broth for 16 hours 
and pDC-CG was purified by a commercially available DNA isolation kit (Plasmid 
MaxiPrep DNA Kit, Norgen Biotek).   
Purified pDC-CG-U6 was reconfirmed by restriction enzyme digestion in three separate 
reactions with enzymes: Sph I and Pml I double digestion, which produced expected 
fragments of 4992 and 316 bp; digestion with Bam HI, which produced expected visible 
fragments of 3570 bp, 809 bp, 635 bp, and 198 bp; and digestion with Eco RI which 
linearized the vector and produced a single band on the gel corresponding to 5308 bp, or 
the full length of the pDC-CG-U6. 
Since the U6 promoter, inserted into pDC-CG-U6, was generated by PCR we sequenced 
this region of the vector to ensure the absence of any mutations. For this purpose, the 
purified vector was sent to a core facility (York University Core Molecular Biology and 
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DNA Sequencing Facility) along with the primer 5`AGCATGCAATTGCCCCCAGTG-
GAAAGACG3`. The returned sequence encompassed the entire U6 promoter, as well as 
a region extending beyond the downstream MCS, and was an absolute match to the 
expected sequence of the U6 promoter. 
1.2.4 Construction of shRNA DNA templates and cloning into pDC-CG-U6 
The design of shRNAs, in the 5` to 3` orientation, was as follows: sense strand, which 
was homologous to the targeted region within EndoG mRNA; a short loop region 
(UUCAAGAGA); and the antisense strand, which was perfectly complementary to the 
target sequence. To facilitate shRNA expression we cloned corresponding DNA 
templates into the pDC-CG-U6 vector. 
DNA templates for shRNA expression were constructed by annealing pairs of 
complementary oligomers (Integrated DNA Technologies) to create dsDNA molecules 
that encoded the following (5` to 3`): Eco RI recognition sequence, sense strand, loop 
region, antisense strand, RNA Pol III terminator sequence, and the Pst I recognition 
sequence. The dsDNA sequences were 63bp long with short single stranded overhangs on 
either end, which were homologous to Eco RI and Pst I-generated sticky ends.  
Digestion of pDC-CG-U6 by Eco RI and Pst I restriction nucleases facilitated the 
subsequent ligation of shRNA DNA templates in the correct orientation, directly 
downstream of the U6 promoter. In total, seven pDC-CG-U6-based vectors were 
constructed in this manner, six of which contained unique DNA templates for the 
expression shRNAs directed against EndoG mRNA and one negative control vector that 
contained a DNA template for the expression of a shRNA without a complement in the 
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human transcriptome. The negative control shRNA target was 5`ACUACCGUUGUUA-
UAGGUG3`. All of the pDC-CG-U6-shRNA vectors were sequenced, as described 
previously, to ensure template sequence fidelity. 
The pDC-CG-U6-shRNA vectors were amplified in E. coli DH5α and subsequently 
purified by a commercially available plasmid isolation kit (Plasmid MaxiPrep DNA Kit, 
Norgen Biotek). To ensure compatibility of plasmid DNA preps for the transfection 
procedure, the protocol included an endotoxin removal component (as per manufacturer’s 
instructions). 
1.2.5 Cell culture 
HeLa cells were maintained in 150 mm, 24-well or 6-well standard culture dishes, 
growing in a monolayer. Culture medium was Gibco’s minimum essential medium 
(MEM) supplemented with 10% (v/v) foetal bovine serum (FBS) (PAA Labs), 
antimycotic-antibiotic (1X, Invitrogen), GlutaMAXTM (1X, Invitrogen) and with sodium 
bicarbonate (3.7 g/l). Cultures were incubated in a 5% CO2/air mixture at 37 °C. 
1.2.6 Transfection of plasmids into subconfluent HeLa cells 
HeLa cells were plated in 24-well plates so that they were 50% confluent on day of 
transfection. Individual plasmids (250 ng/well) were mixed with Opti-MEM I Reduced 
Serum Medium without serum to a final volume of 50 µL. Next, 1 µL of Lipofectamine 
2000 (Invitrogen) was diluted in 50 µL Opti-MEM I Reduced Serum Medium. The 
diluted plasmids were then combined with the diluted Lipofectamine 2000 and left to 
incubate for 20 minutes at room temperature. The plasmid/lipofectamine mixture were 
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then added to each well and mixed into the medium by gentle rocking. Six hours after 
transfection, the medium was changed with fresh medium. 
1.2.7 Transfection of plasmids into near-confluent HeLa cells 
HeLa cells were plated in 6-well plates so that they were 90% confluent on day of 
transfection. Individual plasmids (4 µ g/well) were mixed with Opti-MEM I Reduced 
Serum Medium without serum to a final volume of 250 µL. Next, 5 µL of Lipofectamine 
2000 (Invitrogen) was diluted in 250 µL Opti-MEM I Reduced Serum Medium. The 
diluted plasmids were then combined with the diluted Lipofectamine 2000 and left to 
incubate for 20 min at room temperature. The plasmid/lipofectamine mixture were then 
added to each well and mixed into the medium by gentle rocking. Six hours after 
transfection medium was changed with fresh medium. 
1.2.8 DNA/RNA isolation 
Medium was aspirated and HeLa monolayers were washed twice with 1X phosphate 
buffered saline (PBS), pH7.4. A solution from a commercially available kit 
(RNA/DNA/Protein Purification Kit, Norgen Biotek) was used to lyse cells directly on 
the plate. Entire lysate was collected and applied to a purification column supplied by the 
manufacturer and recommended protocol was followed as specified. DNA and RNA were 
eluted in separate fractions and examined for quality and quantity by agarose gel 
electrophoresis and spectrophotometry, respectively. 
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1.2.9 Quantitative PCR analysis  
Quantitative PCR (qPCR) was performed with the Bio-Rad iCycler thermocycler on 3 µL 
of each DNA elution using the iQ SYBR Green Supermix (Bio-Rad) with 300 nM of 
primers specific for the GFP gene encoded on the plasmid, F 5`GATCACATGAAGC-
AGCACGA3` and R 5`GATGTTGCCATCCTCCTTGA3`. The human 5S gene (Fwd 
primer 5`GCCATACCACCCTGAACG3` and Rev primer 5`AGCCTACAGCACCCG-
GTATT3`) was used for normalization and the comparative threshold method was used 
to assess the relative abundance of the plasmids at each time point.  The total reaction 
volume per sample was 20 µL, and the PCR protocol was as follows: 15 minutes at 95oC 
for enzyme activation, then 40 cycles of 15 seconds at 95oC, 30 seconds at 60oC and 45 
seconds at 72oC. Melt curve analysis was performed by relative fluorescence assessment 
at 0.5oC increments with a 10 second duration, starting at 57oC and continuing for 80 
increments. 
1.2.10 Reverse transcription followed by qPCR 
Three µL of the total RNA elution was used in the reverse transcription (RT) reaction 
using the Superscript III system (Invitrogen). In the first step, RNA was mixed with 0.5 
µL of 100 mM oligo(dT) 18-mer primer (IDT) and the reaction volume was completed to 
10 µL using DNase/RNase free water. Denaturing at 70oC for 5 minutes was followed by 
cooling at 4oC for five minutes. At this step, 0.1 µL of the reverse transcriptase 
Superscript III (SSIII, Invitrogen) was added to the reaction in a mixture with 4 µL of the 
5X First Strand Buffer, 2 µL of 0.1 M Dithiothreitol, 1 µL of 10 mM dNTPs and 2.9 µL 
of water. After the reaction mixture was completed, temperature was increased to 25oC 
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for five minutes and then increased again to 42oC for 60 minutes, followed by 15 minutes 
at 70oC and an indefinite hold at 4oC.   
The qPCR detection of GFP transgene expression levels was carried out using the human 
S15 for normalization and the comparative threshold method was used to assess the 
relative abundance of GFP mRNA at each time point. The primers used for detection of 
GFP copy DNA were F 5`GATCACATGAAGCAGCACGA3` and R 
5`GATGTTGCCATCCTCCTTGA3` and for S15 copy DNA F 5`TTCCGCAAGTTCA-
CCTACC3` and R 5`CGGGCCGGCCATGCTTTACG3`. The iQ SYBR Green Supermix 
(Bio-Rad) was used for the qPCR with 300 nM of primers, as described above for DNA 
analysis. Levels of EndoG mRNA were also interrogated at each time point using the 
primers: F 5`GACGACACGTTCTACCTGAGCAACGT3` and R 5`CCAGGATCAG-
CACCTTGAAGAAGTG3`. The qPCR protocol for EndoG cDNA amplification varied 
slightly to protocol described previously due to the requirement of a higher primer 
annealing temperature, which was set at 65oC. 
1.2.11 EndoG activity assay 
Cultured HeLa cells, transfected with test and control pDC-CG-U6-shRNA vectors, were 
grown to near confluence in 6-well standard tissue culture plates. Medium was aspirated 
and cells were washed three times with ice-cold 1X PBS. Two-hundred µL of the single 
detergent buffer (50 mM Tris-CI pH 8.0, 150 mM NaCI, 0.02% sodium azide, 100 
µg/mL PMSF, 1 µ g/mL aprotinin and 1% Nonidet P-40) was added directly to cell 
monolayers and plates were incubated at 4oC for 20 minutes. Lysates were collected by 
pipetting into a chilled Eppendorf tube, followed by centrifugation at 12,000g for 2 
minutes at 4oC. Soluble proteins from the supernatant were collected and stored at -70oC. 
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Total protein concentration was determined using the Pierce 660 nm Protein Assay Kit 
(Thermo Scientific) by mixing 1.5 mL of reagent to 0.1 mL of diluted samples, followed 
by incubation at room temperature for five minutes and spectrophotometry at 660 nm. 
Quantification was facilitated by standard curve analysis, using the BSA protein as a 
standard. 
One µg of linearized plasmid target (pDC-CG-U6 digested with Eco RI) was incubated 
with 20 µ g of total protein from cell extracts for 0, 30, 90, or 180 minutes at 37oC. Each 
reaction was supplemented with 1 mM MgCl2 to select for EndoG activity (Kieper et al., 
2010). Ten µL of each 50 µL reaction was loaded on a 1% DNA agarose gel and 
examined after electrophoresis.  
1.2.12 Cell counting 
Medium was aspirated from HeLa cells cultured in 24-well standard tissue culture plates 
and monolayers were washed three times with 1X PBS. Cells were lifted with 200 µL of 
Gibco’s 0.05% Trypsin-EDTA (1x) and counted on the haemocytometer counting 
chamber using the Olympus CK 2 inverted microscope for magnification.  
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1.3 Results 
 
1.3.1 – Strategy of EndoG Knockdown by RNAi 
 
1.3.1.1 Selection of RNAi targets within EndoG mRNA 
To select appropriate regions on the EndoG mRNA for targeting by RNAi a proprietary 
algorithm (Invitrogen’s BLOCK-iT™ RNAi Designer tool) was used. Six regions of 
EndoG mRNA were identified as possible targets (Fig. 1.1). Targeting was limited to the 
open reading frame (ORF) of EndoG, with a minimum and maximum G/C content of 
candidate sequences set at 35% and 55%, respectively. Basic Local Alignment Search 
Tool (Human – Homo sapiens database) was used to ensure only unique regions of 
EndoG were targeted. The control targeted sequence was not encoded in the human 
genome: 5`-ACUACCGUUGUUAUAGGUG-3`. 
 
Figure 1.1: Full length EndoG mRNA (1145 nt). The coding sequence (in red) spans 
from nucleotides 186 to 1079 (894 nt). Relative positions of RNAi targets are indicated, 
along with the target sequences (and nucleotide positions in parentheses, in the 5` - 3` 
direction).  
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1.3.1.2 Design of RNAi effectors for EndoG knockdown 
 
Identification of suitable targets within EndoG mRNA (Fig. 1.1) enabled us to design 
short-hairpin RNAs (shRNAs) that specifically antagonized these regions. Six shRNAs 
targeting EndoG mRNA, plus a negative control shRNA, were designed based on the 
following scheme, in the 5` to 3` direction: sense strand (identical to target sequence), 
loop region (9 nt), antisense strand (perfectly complementary to target sequence) 
(illustrated in Fig. 1.2, using target sequence at nt 644 of EndoG mRNA as a 
representative example).  
 
 
 
 
Figure 1.2: Construction design of a representative shRNA targeting EndoG mRNA at 
nucleotide position 644 (5` to 3` direction). The sense strand (blue border) is identical to 
the selected targeting site (black border), while the antisense strand (red border) is its 
perfect complement. Annealing between sense and antisense strands results in a hairpin 
structure, characterized by a single stranded loop region (green border).  
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1.3.2 – Construction of Plasmids for Expression of shRNAs Directed Against EndoG  
 
1.3.2.1 Engineering the U6 (RNA Pol III) promoter into assay plasmid pDC-CG 
The assay plasmid pDC-CG encoded a GFP reporter gene under the control of the 
cytomegalovirus immediate-early (CMVie) promoter/enhancer (Fig. 1.3). To drive 
expression of shRNAs directed against EndoG (or control shRNA), we inserted the U6 
RNA Pol III promoter into our assay plasmid, pDC-CG, directly upstream of the GFP 
expression cassette. This was accomplished in several steps, as outlined in Figure 3, and 
resulted in the creation of pDC-CG-U6, an shRNA expression vector. 
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Figure 1.3: Design scheme used for the construction of the pDC-CG-U6 vector for 
expression of shRNAs and AcGFP. The RNA Pol III promoter, U6, was amplified by 
PCR from a commercially available vector (pSilencer 2.1 Neo U6, Ambion) and 
subsequently cloned into the pUC19 vector. Primers were flanked by recognition 
sequences for Mfe I and Eco RI (5` to 3`) which facilitated excision of the promoter from 
pUC19 and its insertion into an Eco RI site in the pDC-CG vector. 
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The resultant vector pDC-CG-U6 was confirmed by PCR (Fig. 4A), restriction enzyme 
digestion (Fig. 4B) and sequencing (Fig. 5). 
A                 B 
                           
 
 
 
 
 
 
 
 
Figure 1.4: A) Screening for U6 promoter in the pDC-CG vector from E. coli DH5α 
colonies by end point PCR. Amplicon size from clone 46 was 1660 bps, confirming a 
single insertion of the promoter in the correct orientation. B) Confirmation of pDC-CG-
U6 by restriction enzyme digestion. Sph I and Pml I (S & P) double digestion produced 
expected fragments of 4992 and 316 bps; digestion with Bam HI (Bam) produced 
expected visible fragments of 3570 bps, 809 bps, 635 bps, and 198 bps; digestion with 
Eco RI (Eco) linearized the vector and produced a single band on the gel corresponding 
to 5308 bps, or full length of the pDC-CG-U6. 
 
 
 
 
 
 
Figure 1.5: Full length sequence of the U6 RNA Pol III promoter confirmed by sequence 
analysis to be 100% identical to the insert in pDC-CG-U6. 
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5`.ggcatgcaattgcccccagtggaaagacgcgcaggcaaaacgcaccaggtgacggagcgtgaccgcgcgccgagcgcgcgccaaggtcg
ggcaggaagagggcctatttcccatgattccttcatatttgcatatacgatacaaggctgttagagagataattagaattaatttgactgtaaaca
caaagatattagtacaaaatacgtgacgtagaaagtaataatttcttgggtagtttgcagttttaaaattatgttttaaaatggactatcatatgctt
accgtaacttgaaagtatttcgatttcttgggtttatatatcttgtggaaaggacgcgggatccgaattcg. 3` 
48 
 
1.3.2.2 Design and incorporation of EndoG-targeting shRNA templates into pDC-CG-U6 
We made use of Eco RI and Pst I recognition sites immediately downstream of the U6 
promoter to insert templates for shRNA expression (Fig. 1.6A). In total, seven plasmids 
based on the same backbone of pDC-CG-U6 were constructed, but each of the plasmids 
encoded a different shRNAs (Fig. 1.6B). Six of these plasmids carried templates for 
shRNAs directed against EndoG mRNA (from Fig. 1.1) and one was a negative control 
that encoded a non-targeting shRNA. Plasmids that carried shRNAs targeting EndoG 
were named p1 through p6, reflecting the relative positions (5` to 3` direction) of the 
sequence they targeted on the EndoG mRNA and the negative control plasmid was 
named pNC. All of the constructed plasmids were confirmed by DNA sequencing.  
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Figure 1.6: A) Representative shRNA template inserted between the Eco RI and Pst I 
sites of pDC-CG-U6, immediately downstream of the U6 promoter. In the example, 
shRNA is targeted at nucleotide 644 of EndoG mRNA. B) Representative map of pDC-
CG-U6 showing (in yellow) the position of the inserted shRNA template downstream of 
the U6 promoter (red). Seven plasmids (p1 – p6 and pNC) were made, six of which 
carried shRNAs targeting EndoG and one negative control. 
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1.3.3 – Evaluating stability of plasmid DNA carrying shRNAs directed against 6 regions 
of EndoG mRNA 
 
1.3.3.1 Relative cellular abundance of pDNA over time after transfection of sub-confluent 
HeLa cells  
 
As described in the previous section, seven plasmids that were based on the pDC-CG-U6 
backbone were constructed, six of which encoded a unique shRNA targeting EndoG 
mRNA (p1 through p6) and a negative control plasmid (pNC), which encoded an shRNA 
without a complement in the human transcriptome. In order to assess their relative 
stability in replicating mammalian cells, we transfected these plasmids into sub-confluent 
HeLa cells and then monitored their levels at 24-hour intervals over the next four days. 
We used a cationic liposome transfection reagent (Lipofectamine 2000, Invitrogen) and 
replaced the medium 6 hours after starting transfection. For the transfection, we used 200 
ng of each plasmid per well of 40-50% confluent HeLa cells, cultured in 24-well standard 
tissue culture plates. Each plasmid was transfected into 15 well of cells in order to assay 
triplicate samples at each time point tested: 2, 24, 48, 72, and 96 hours post-transfection. 
In total, 105 individual samples were assayed.  
The DNA that was isolated from each sample was analyzed by qPCR in two separate 
reactions. In one, primers specific for the backbone of the transfected pDNA were used, 
whereas in the other primers for the cellular 5S rRNA gene were used. Relative pDNA 
abundances were inferred using the equation 2 (^Ct, 5S – Ct, pDNA), where Ct, 5S 
represents the threshold cycle of the PCR using 5S-specific primers and Ct, pDNA 
represents the threshold cycle of the PCR using pDNA-specific primers from a single 
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sample. The relative pDNA abundances, normalized with the 5S gene were plotted in 
Figure 1.7, allowing for inter-sample comparison.  
 
Figure 1.7:  Effect of EndoG targeting on pDNA stability. Relative cellular abundance of 
test plasmids (p1 through p6, in blue) and the negative control plasmid (pNC, in red) at 2, 
24, 48, 72 and 96 hours after transfection of 40-50 % confluent HeLa cells (cultured in 
24-well plates) with 200 ng of each plasmid. Levels were measured by quantitative PCR 
using the cellular 5S rRNA gene for normalization. Values on x-axis are not indicative of 
actual pDNA copies, as they were inferred based on the equation 2 (^Ct, 5S – Ct, pDNA), 
where Ct, 5S represents the threshold cycle of the PCR using 5S-specific primers and Ct, 
pDNA represents the threshold cycle of the PCR using pDNA-specific primers from a 
single sample. Therefore, the x-axis represents relative values of normalized plasmid 
abundances that allowed for inter-sample comparison. Error bars indicate SD. 
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The control vector (pNC) showed a time-dependent decrease with respect to cellular 
DNA (5S gene) after reaching peak levels at 24 hours post-transfection (Fig. 1.7). This 
indicated a loss of pDNA copy number from transfected cells, assuming that 5S rRNA 
gene content was correlated to cell number. It is important to note that cellular gene 
content may not have correlated exactly to the cell number due to the possibility of 
unequal cellular DNA replication rates.  
The observed decrease of relative pNC abundance was greatest between 24 and 48 hours 
post-transfection (Table 1.2). In contrast, test plasmids did not show an equivalent drop in 
copies, relative to cellular DNA, between these two time points (24 and 48 hours) (Fig. 
1.7, Table 1.2). Relative plasmid abundance for test plasmids either did not change during 
this window (p2, p3, p4, and p5) or actually increased (p1 and p6) (Table 1.2). 
Table 1.2 – Ratios of relative cellular abundances of test and control pDNA vectors 
between 48 and 24 hours post transfection (p.t.) of sub-confluent HeLa cells. The greatest 
difference was observed for pNC, where the ratio is 0.38 compared to ~1 for the test 
pDNA vectors (p1 through p6). 
pDNA 
vector 
Relative cell. abundance of 
pDNA at 48 h p.t./Relative 
cell. abundance of pDNA at 
24 h p.t. 
p1 1.70 
p2 1.20 
p3 0.99 
p4 0.94 
p5 0.79 
p6 1.60 
pNC 0.38 
Differences between the relative pDNA abundances of test and control vectors were also 
observed at 2 at 24 hours post-transfection. Due to the time-frame required for shRNA 
53 
 
expression and action it is unlikely these effects were related to EndoG-targeting and they 
were most likely the result of variable transfection efficiencies (not assayed) between 
individual plasmids, which was expected considering the transfection procedure used. 
1.3.3.2 Abundance of pDNA over time after transfection of sub-confluent HeLa cells 
without cellular normalization 
 
The relative pDNA abundance in each sample of transfected cells was also examined 
without normalizing with the 5S rRNA cellular gene in order to eliminate any effects that 
unequal replication of cellular DNA may have on the perceived pDNA stability. In 
addition, this eliminated the effects of dilution by mitosis on perceived pDNA stability 
and allowed for examining the “absolute” plasmid abundance per well of transfected 
HeLa cells (Fig. 1.8). 
Briefly, for each sample, regardless of condition or time-point assayed, DNA was 
extracted from the entire population of HeLa cells growing in a single well. Equal 
proportions of each DNA sample were interrogated by qPCR using primers specific for 
the transfected pDNA backbone and the relative abundance of pDNA in each sample was 
inferred by the equation 2 -^Ct, pDNA, where Ct, pDNA represents the threshold cycle of 
the reaction. The calculated pDNA abundance for each sample was representative of the 
absolute amount of pDNA in a single well of HeLa cells. Therefore, the values generated 
were used to compare relative pDNA abundance per well of transfected cells between 
different conditions and time-points.  
We observed that the abundance per well (or the absolute quantity) of the negative 
control plasmid (pNC, in red) decreased between 24 and 48 hours, whereas it remained 
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constant for all of the test plasmids (p1 through p6, in blue) (Fig. 1.8, Table 1.3). These 
results indicated that pNC was lost from the transfected HeLa cells, rather than diluted, 
whereas the EndoG-targeting plasmids were neither diluted nor lost between 24 and 48 
hours post-transfection of sub-confluent HeLa cells (Table 1.2, Table 1.3). 
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Figure 1.8: Effect of EndoG targeting on pDNA stability disregarding normalization of 
data against cellular DNA. PCR quantification of plasmid DNA in each well of 
transfected cells (p1 through p6, in blue and pNC, in red), disregarding normalization 
with cellular DNA, at 2, 24, 48, 72 and 96 hours after transfection of 40-50 % confluent 
HeLa cells (cultured in 24-well plates) with 200 ng of each plasmid. The abundance of 
pDNA in each sample was inferred by the equation 2 -^Ct, pDNA, where Ct, pDNA 
represents the threshold cycle of the PCR using pDNA-specific primers. The calculated 
pDNA abundance for each sample was representative of the absolute amount of pDNA in 
a single well of HeLa cells, although the values on x-axis are relative and not indicative 
of actual pDNA copies.  Error bars indicate SD. 
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Table 1.3 - Ratios of absolute abundances of test and control pDNA vectors between 48 
and 24 hours post transfection (p.t.) of sub-confluent HeLa cells. The greatest difference 
was observed for pNC, where the ratio is 0.54 compared to ~1 for the test pDNA vectors 
(p1 through p6). 
pDNA 
vector 
Abs. pDNA abundance 
at 48 h p.t./Abs. pDNA 
abundance at 24 h p.t. 
p1 1.28 
p2 1.15 
p3 0.89 
p4 1.01 
p5 1.16 
p6 1.21 
pNC 0.54 
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1.3.3.3 Relative cellular abundance of pDNA over time after transfection of near-
confluent HeLa cells  
 
To test whether the observed difference in stability between plasmids carrying shRNAs 
directed against EndoG and the negative control plasmid was dependent on initial cell 
density at the time of transfection reagent exposure, we repeated the above described 
experiment in near-confluent HeLa cells. Also, for this experiment we reduced the pool 
of plasmids carrying shRNAs against EndoG to two (p2 and p6), while using the same 
negative control plasmid (pNC), in order to reduce sample handling (from 105 samples to 
36). Plasmids p2 and p6 were chosen because they encoded shRNAs against discrete 
regions of EndoG mRNA that were separated by 344 nucleotides. In addition, we did not 
assay past 72 hours to avoid excessive necrotic cell death. 
Figure 1.9: Effect of EndoG targeting on pDNA stability following transfection of near-
confluent cells. Relative abundance of plasmids pNC, p2 and p6 at 2, 24, 48 and 72 hours 
after transfection of near-confluent HeLa cells (cultured in 6-well plates) with 4 µg of 
each plasmid. Levels were measured by quantitative PCR using the 5S gene for 
normalization. All plasmids showed similar abundance levels at each time point assayed. 
All plasmids showed a time dependent decrease in copy number. Error bars indicate SD. 
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The reasoning for repeating the experiment in HeLa cells that were near-confluent at time 
of transfection, as opposed to sub-confluent, was the observation that cells seeded at a 
lower density at the outset of the experiment were more sensitive to the cytotoxicity of 
the cationic liposome transfection reagent (Lipofectamine2000, Invitrogen). These effects 
are illustrated in Figure 1.16, where it is clear that sub-confluent HeLa cells do not 
proliferate normally up to 48 hours following treatment with the transfection reagent.  
As we can see from Figure 1.9, when near-confluent cells were transfected, the plasmid 
abundances, relative to the cellular 5S rRNA gene, were similar between all three vectors 
(pNC, p2 and p6), regardless of encoded shRNAs, and decreased in a time-dependent 
fashion. No differences in pDNA stability between test and control pDNA vectors were 
observed during the period between 24 and 48 hours following transfection (Table 1.4). 
This result was in direct contrast to the previous observation made from the experiment 
on HeLa cells that were sub-confluent at time of transfection. This indicated that cell 
density was an important factor in determining whether targeting of EndoG had a positive 
or neutral effect on pDNA stability.  
Table 1.4 – Ratios of relative cellular abundances of test (p2 and p6) and control pDNA 
vectors between 48 and 24 hours post transfection (p.t.) of near-confluent HeLa cells. The 
test vector p6 and the control pNC showed equivalent decreases between 24 and 48 hours 
following transfection. 
pDNA 
vector 
Relative cell. abundance 
of pDNA at 48 h 
p.t./Relative cell. 
abundance of pDNA at 
24 h p.t. 
p2 0.43 
p6 0.35 
pNC 0.33 
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1.3.4 – Evaluating transgene expression from plasmids carrying shRNAs directed against 
EndoG mRNA in HeLa cells sub-confluent at time of transfection 
 
1.3.4.1 Relative expression of GFP reporter gene normalized with cellular mRNA 
 
To evaluate reporter gene GFP expression in cells transfected with test and negative 
control plasmids, RNA that was isolated from HeLa cell monolayers was subjected to a 
reverse transcriptase (RT) reaction to generate cDNA and subsequently amplified by 
qPCR, using primers specific for the GFP transcript. GFP expression was normalized 
with the expression of the ribosomal protein S15 cellular gene in each sample, using the 
equation 2 (^Ct, S15 – Ct, GFP) and the resultant values plotted in Figure 1.10.  
Reporter gene expression was higher in cells transfected with test plasmids (p1 – p6) at 
24 and 48 hours post transfection, relative to cells transfected with the negative control 
plasmid (pNC)  when expression was normalized with the expression of a cellular 
housekeeping gene (S15) (Fig. 1.10).  
 
60 
 
 
Figure 1.10: Effect of EndoG targeting on reporter gene expression. Relative GFP 
expression in cells transfected with the negative control plasmid (pNC) and test plasmids 
(p1 - p6) assayed at 24 hour intervals over four days. Levels of GFP mRNA were 
measured by RT-qPCR and normalized with the expression of the S15 gene using the 
equation 2 (^ Ct, S15 – Ct, GFP). Error bars indicate SD. 
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1.3.4.2 Relative expression of GFP reporter gene normalized with cellular mRNA and 
against cellular pDNA abundance 
 
To compare the levels of GFP expression with respect to the levels of intracellular pDNA 
that encoded the transgene, GFP mRNA expression was normalized with pDNA 
abundance using matched RNA and DNA samples isolated from a single well of 
transfected HeLa cells. The equation used for calculating relative GFP mRNA expression 
values was 2^[(Ct, S15 – Ct, GFP) – (Ct, 5S – Ct, pDNA)], where Ct, “sequence name” 
represents the threshold cycle of each qPCR using primers specific for S15 and GFP 
cDNAs, the transfected pDNA backbone and the cellular 5S rRNA gene. 
As we can see from Figure 1.11, all test plasmids (in blue) expressed more GFP mRNA 
per plasmid copy relative to the negative control plasmid (in red) at 24 hours post 
transfection. Furthermore, GFP mRNA expression with respect to plasmid copy number 
reached its peak at 24 hours post transfection in cells transfected with plasmids carrying 
shRNA against EndoG, which was not the case in cells transfected with the negative 
control plasmid (pNC). It is also important to note that GFP expression did not differ 
between EndoG-targeting plasmids, p2 or p6, and the negative control plasmid, pNC, at 
any of the assessed time-points following transfection of near-confluent HeLa cells (data 
not shown).  
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Figure 1.11: Effect of EndoG targeting on reporter gene expression normalized against 
pDNA abundance. Relative GFP mRNA expression normalized against plasmid 
abundance for the negative control plasmid (pNC) and test plasmids (p1 - p6) assayed at 
24-hour intervals over four days. Levels of GFP mRNA were measured by RT-qPCR and 
normalized using the expression of the S15 gene and plasmid abundance was normalized 
using the 5S gene. The equation used for calculating relative GFP mRNA expression 
values was 2 [^(Ct, S15 – Ct, GFP) – (Ct, 5S – Ct, pDNA)]. Error bars indicate SD. 
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1.3.5 – Evaluating EndoG levels in cells transfected with plasmids carrying shRNAs 
targeting EndoG 
 
1.3.5.1 Measuring cellular levels of EndoG mRNA in sub-confluent HeLa cells following 
transfection 
 
Figure 1.12: Effect of EndoG targeting on cellular EndoG mRNA expression levels. 
Relative EndoG mRNA expression per cell in cells transfected with the negative control 
plasmid (pNC) and test plasmids (p1 – p6). Levels of EndoG mRNA were measured by 
RT-qPCR and normalized with the expression of the S15 gene using the equation 2 (^Ct, 
EndoG – Ct, S15). Error bars indicate SD. 
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Looking at Figure 1.12, specifically at cells transfected with the negative control plasmid 
(pNC) it is obvious that EndoG mRNA levels fluctuate somewhat and importantly that 
they increased between 24 and 48 hours after transfection (Table 1.5). Conversely, 
EndoG levels decreased during that same period (below those observed for the negative 
control) in cells transfected with test plasmids p1 and p2, confirming the EndoG 
knockdown (Fig. 1.12). Interestingly, in cells transfected with test plasmids p3, p4, p5 
and p6 the levels of EndoG mRNA appeared to be higher than in cells transfected with 
the negative control at 24 hours post transfection and they were more or less equal 
subsequently. However, even in cells transfected by these test plasmids, EndoG levels did 
not change between 24 and 48 hours post-transfection, whereas they increased in cells 
that were transfected with the negative control plasmid (Table 1.5). Therefore, EndoG 
mRNA was upregulated following transfection of pNC into sub-confluent HeLa cells. 
Table 1.5 - Ratios of EndoG mRNA expression between 48 and 24 hours post 
transfection (p.t.) of sub-confluent HeLa cells with test (p1 through p6) and control 
pDNA vectors. Cells transfected pNC show upregulation of EndoG between these time 
points, an effect that is absent from cells transfected with EndoG-targeting vectors. 
pDNA 
vector 
EndoG mRNA exp. at 48 
h p.t./EndoG mRNA 
exp. at 24 h p.t. 
p1 0.53 
p2 0.64 
p3 0.93 
p4 1.07 
p5 0.82 
p6 0.94 
pNC 1.62 
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1.3.5.2 Measuring cellular levels of EndoG mRNA in near-confluent HeLa cells following 
transfection 
 
Levels of EndoG mRNA decreased in near-confluent HeLa cells transfected with 
plasmids carrying EndoG targeting shRNAs (p2 and p6) relative to control, which started 
at 24 hours and continued until the end of the experiment (Fig. 1.13). Importantly, 
transfection of the negative control plasmid into near-confluent HeLa cells did not result 
in an associated increase in EndoG mRNA between 24 and 48 hours post-transfection, 
which was observed following transfection of sub-confluent HeLa cells. Therefore, 
EndoG mRNA upregulation was specific to the transfection of pNC into sub-confluent 
HeLa cells. 
 
Figure 1.13: Effect of EndoG targeting on cellular EndoG mRNA expression levels 
following transfection of near-confluent cells. Relative EndoG expression in cells 
transfected with pNC, p2, and p6 assayed at 24 hour intervals over three days. Levels of 
EndoG mRNA were measured by RT-qPCR and normalized using the expression of the 
S15 gene. EndoG mRNA levels in cells transfected p2 and p6 are detectably lower at 24, 
48 and 72 hours post-transfection. Error bars indicate SD. 
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1.3.5.3 Measuring EndoG activity in cells transfected with plasmids carrying shRNAs 
against EndoG mRNA 
 
Incubation of plasmid DNA target (linearized pDNA sequence) with cell extracts of cells 
transfected with either of the p6 (Figure 1.14) or p2 (Figure 1.15) test plasmids resulted in 
a decrease in target DNA degradation relative to cell extracts isolated from cells 
transfected with the negative control plasmid (pNC). This showed that nuclease activity 
was suppressed in cell extracts transfected with p6 or p2. 
 
Figure 1.14: Effect of EndoG targeting on nuclease activity in cell extracts. One µg of 
linearized plasmid target was incubated with 20 µg of total protein from cell extracts of 
cells transfected with p6 (left) or pNC (right) for 0, 30, 90, or 180 minutes at 37oC. Ten 
uL of each 50 µL reaction was loaded on a 1% DNA agarose gel. Each reaction was 
supplemented with 1mM MgCl2. Target pDNA is more intact after incubation with cell 
extracts from cells transfected with p6 than pNC. Samples not spiked with plasmid target 
(in yellow) were also incubated for 180 minutes, showing similar results.   
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Figure 1.15: Effect of EndoG targeting on nuclease activity in cell extracts. One µg of 
linearized plasmid target was incubated with 20 µg of total protein from cell extracts of 
cells transfected with p2 (left) or pNC (right) for 0, 30, 90, or 180 minutes at 37oC. Ten 
uL of each 50 µL reaction was loaded on a 1% DNA agarose gel. Each reaction was 
supplemented with 1mM MgCl2. Target pDNA is more intact after incubation with cell 
extracts from cells transfected with p2 than pNC. Samples not spiked with plasmid target 
(in yellow) were also incubated for 180 minutes, showing similar results.   
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1.3.6 – Measuring cellular growth rate following transfection of sub-confluent HeLa cells  
 
To assess whether targeting of EndoG protected cells from the cytotoxicity of the cationic 
liposome transfection reagent, we measured HeLa cell proliferation (Fig. 1.16) over a 
four day time course following transfection with the EndoG-targeting plasmid, p6, or the 
negative control plasmid pNC. In both transfection conditions the cell numbers did not 
increase between the start of the experiment and 48 hours after transfection, which 
differed from the climbing trajectory observed over the following two days. There were 
no significant differences in cell numbers at any of the points assayed, however it is 
important to note that results from Chapter II of this study showed that EndoG-silencing 
induced a cell proliferation defect in HeLa, which may have masked any protective 
effects.  
 
Figure 1.16: Effect of EndoG targeting on cellular growth following transfection of sub-
confluent cells. Cell counts of HeLa cells cultured in triplicate wells of a 24-well tissue 
culture plate after transfection with 400ng of EndoG-targeting (p6) or negative control 
(pNC) plasmids using Lipofectamine 2000 as a transfection reagent. 
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1.4 Discussion 
The mitochondrial enzyme EndoG has so far been investigated mostly in the context of 
its role in apoptotic cell death, although it has also been implicated in a number of vital 
biological functions (Huang et al, 2002; Huang et al, 2006; Buttner et al., 2007a,b; 
Buzder et al., 2009; McDermott et al., 2011; Zan et al., 2011). Most of the proposed vital 
functions of EndoG require its nuclease action inside nuclei of healthy, non-apoptotic 
cells. Since exogenous DNA occupies the same intranuclear environment as the host 
genomic DNA, the aim of this study was to investigate whether EndoG is a cellular 
defence enzyme, involved in exogenous DNA stability and hence expression of genes 
encoded on that DNA. Specifically, we tested the effects of EndoG depletion on plasmid 
DNA abundance and transgene expression in replicating mammalian cells (HeLa).   
The strategy for this study was to assay plasmid stability within a four day time course in 
cellular backgrounds that either have wildtype (normal) or reduced levels of EndoG. 
Unfortunately, overexpression of EndoG was not an option due to the endogenous 
cytotoxicity of the mature form of EndoG, which non-specifically degrades genomic 
DNA and kills the cell (Winnard et al., 2008). In addition, transfection of pDNA into 
cellular backgrounds that have different EndoG levels at outset of experiment was also 
not considered since EndoG has previously been reported to reduce transfection 
efficiency of mammalian primary and epithelial cells (Buzder et al., 2009).  
To avoid any effects that transfection efficiency, and hence initial cellular abundance of 
plasmid DNA, could have on its perceived longitudinal stability, the experimental design 
was appropriately tailored to synchronize delivery of pDNA with an effector of EndoG 
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silencing. For this purpose, templates for shRNAs that specifically target six distinct 
sequences in the coding region of EndoG mRNA were designed and separately 
engineered into the assay pDNA vectors, along with a template for an shRNA that did not 
have a complement in the human transcriptome. Probing of multiple target sites was done 
to ensure silencing, as there may be some heterogeneity with respect to silencing 
efficiencies based on sequence and location of target (Gavrilov and Saltzman, 2012).  
Apart from shRNA cassettes, all assay pDNA vectors shared an identical backbone that 
included a cassette for the expression of a GFP reporter gene, under the control of the 
CMVie enhancer/promoter. All pDNA vectors were independently transfected into sub-
confluent HeLa cells using a cationic liposome transfection reagent (Lipofectamine 2000, 
Invitrogen). Low initial seeding density ensured that cells could replicate for the entire 
duration of the four-day time course without constraints imposed by the surface area of 
the tissue-culture dish, as HeLa cells grow in a strict monolayer and are contact inhibited 
(Heacock et al., 1984). 
At each time point (24 hour interval), plasmid stability was assayed by quantitative PCR 
and the comparative threshold method was used to infer relative plasmid abundance per 
cell, using a cellular gene for normalization. Although transfection efficiency was not 
assayed, it is probable that two subpopulations of cells were present in each tissue-culture 
well, regardless of plasmid used: cells that took up the plasmid and those that did not. 
Replication of both subpopulations of cells resulted in an increase in cell number over 
time, whereas plasmid vectors, which cannot replicate in HeLa, or any other mammalian 
cells, could not follow suit (Middleton and Sugden, 1994). Therefore, the ratio of plasmid 
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to cellular DNA was lowest at the conclusion of the four-day time-course due to simple 
dilution by mitosis for all plasmids, regardless of EndoG-targeting. 
Interestingly, plasmids that encoded shRNAs targeting EndoG mRNA, showed a 
dissimilar pattern of time-dependent cellular abundance relative to non-targeting control 
plasmid at 24 and 48 hours post-transfection, but were similar thereafter. The relative 
cellular abundance of EndoG-targeting plasmids either stayed the same or slightly 
increased during this interval (24-48 hours post-transfection), while it sharply decreased 
in the case of the non-targeting control. This may have happened as a consequence of 
differential degradation of EndoG-targeting and non-targeting pDNA vectors during this 
time period, but did not exclude other explanations such as differences in replication rates 
of host cells and/or cell viability (Huang et al, 2006; Li et al., 2001).  
If we consider the above described dilution effect, brought on by replication of both 
transfected and non-transfected cells in each well, as the only factor responsible for the 
decrease of the ratio between plasmid and cellular DNA, then only the relative number of 
plasmids should have decreased between time points, but the absolute number of 
plasmids in a single well should have stayed the same, regardless of cell number. On the 
other hand, if absolute plasmid abundance decreased between time points, this could not 
be explained by a dilution effect, but rather pDNA degradation. 
In order to test for this, plasmid abundance per well over the entire time course of the 
experiment was assayed by uncoupling plasmid DNA quantification from normalization 
with a cellular gene. It was observed that the abundance per well (or the absolute 
quantity) of the non-targeting control plasmid decreased between 24 and 48 hours, 
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whereas it remained consistent for all of the EndoG-targeting plasmids. This meant that 
during this time interval the relative cellular abundance of the non-targeting control 
plasmid did not decrease as function of simple dilution by mitosis, but much more likely 
as a consequence of degradation. In contrast, during the same time period the absolute 
abundance of EndoG-targeting plasmids stayed the same, suggesting a protective effect. 
Interestingly, as mentioned previously the relative abundance of EndoG-targeting 
plasmids normalized with cellular DNA also stayed consistent during this window, which 
implies that the plasmid was not diluted by cellular replication, which would be expected 
since doubling time of HeLa cells is one day (Meck et al., 1976). 
Although EndoG knockdown produced a measurable effect on plasmid stability in HeLa 
cells, the mechanism behind the observation required further testing. It would have been 
convenient to assume that EndoG had an effect on plasmid DNA levels by specifically 
targeting exogenous DNA with its nuclease action, but this assumption failed to consider 
additional factors. Namely, the transfection reagent used to introduce pDNA into HeLa 
cells was a cationic liposome (Lipofectamine 2000) the use of which has been 
experimentally shown to increase cellular levels of reactive oxygen species (ROS), lead 
to mitochondrial membrane depolarization and release of proapoptotic factors from the 
mitochondrial intermembrane space (Kongkaneramit et al., 2008; Takano et al., 2003; 
Aramaki et al., 2000; Aramaki et al., 1999; Iwaoka et al., 2006; Takano et al., 2001).  
The main cellular localization of EndoG is in the mitochondrial intermembrane space, 
from which it is released following apoptotic triggers, such as ROS, that collapse 
mitochondrial membrane potential (Arnoult et al., 2003; Zhao et al., 2009; Marzetti et al., 
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2008; Higgins et al., 2009). Apoptotic triggers also upregulate gene expression of several 
mitochondria associated proapoptotic factors, including EndoG (Li et al., 2004; Zhao et 
al., 2009; Zhang et al., 2009; Lee et al., 2008; Mercer et al., 2010; Papa and Germain, 
2011; Apostolov et al., 2011; Wu et al., 2010; Mitra et al., 2012; Ho et al., 2009; Yeh et 
al., 2011). Upon its release from mitochondria, EndoG quickly translocates to the nucleus 
and degrades DNA in a non-specific fashion (Arnoult et al., 2003; Bahi et al., 2006; 
Strauss et al., 2008). Therefore, low cell density at the outset of the experiment, which 
exaggerated cytotoxic effects of Lipofectamine 2000, could have triggered EndoG-
dependent cell death in cells that took up plasmid DNA.   
Supporting this explanation is the EndoG mRNA expression pattern observed for cells 
transfected with the EndoG-targeting and non-targeting control plasmids. Namely, 
between 24 and 48 hours post-transfection, EndoG is upregulated in cells transfected with 
the non-targeting control plasmid, suggesting a response to an apoptotic trigger, while in 
cells transfected with EndoG-targeting plasmids this upregulation was not observed, 
presumably as a consequence of RNAi targeting. This is consistent with previously 
reported upregulation of EndoG expression as a marker of apoptotic cell death (Li et al., 
2004; Zhao et al., 2009; Zhang et al., 2009; Lee et al., 2008; Mercer et al., 2010; Papa 
and Germain, 2011; Apostolov et al., 2011; Wu et al., 2010; Mitra et al., 2012; Ho et al., 
2009; Yeh et al., 2011). At time points after 48 hours post-transfection, these effects 
dissipated (most likely because surviving cells normalized their gene expression) and 
EndoG expression pattern was similar at 72 and 96 hours post-transfection in all 
transfected cells. 
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This would explain why absolute copy number (plasmid abundance per well) of the non-
targeting plasmid was reduced at 48 hours, relative to 24 hours after transfection. The 
cells that took up the plasmid most likely succumbed to apoptosis due to the associated 
uptake of the cationic liposome, as the increase in EndoG mRNA expression implied 
(Kongkaneramit et al., 2008; Takano et al., 2003; Aramaki et al., 2000; Aramaki et al., 
1999; Iwaoka et al., 2006; Takano et al., 2001). This would also explain why EndoG-
targeting plasmids showed increased stability relative to the non-targeting control, as the 
shRNA they encoded could have attenuated EndoG-dependent cell death by reducing 
cellular levels of EndoG (Li et al., 2004; Wang et al., 2008; Basnakian et al., 2006).  
A similar effect was reported for both aggressive prostate and breast cancer cells, where 
low expression levels of EndoG correlated with resistance of these cancer cell lines to 
chemotherapeutic agents cisplatin and etoposide, both of which induce cell death in part 
by increasing intracellular levels of ROS (Wang et al., 2008; Basnakian et al., 2006). 
Furthermore, both reports showed experimentally that silencing of EndoG by siRNA in 
expressing cell lines could attenuate cell death after exposure to these chemotherapeutics 
(Wang et al., 2008; Basnakian et al., 2006). The central role of EndoG in mitochondria 
associated apoptosis has been well documented and several studies have shown that 
EndoG silencing can make cultured cells refractive to apoptosis triggers (Apostolov et al., 
2011; Kim et al., 2008; Higgins et al., 2012). Therefore, the differential loss of copies 
observed between EndoG-targeting and non-targeting vectors could be due to the non-
specific nuclease action of EndoG on chromatin (and all other nucleic acids in the 
nucleus) as a result of programmed cell death, rather than targeted action against 
exogenous DNA.      
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In order to test whether the observed difference in plasmid stability between the non-
targeting control and EndoG-targeting vectors was a result of specific targeting of 
exogenous DNA by EndoG, or simply a byproduct of the cytotoxic nature of the 
transfection reagent used in the experiment, a new experimental design was devised. 
Namely, proapoptotic effect of Lipofectamine 2000 was minimized by increasing the 
starting cell density of HeLa to near confluence, which was specifically recommended in 
the manufacturer’s user manual.  
In this experiment, plasmid abundance, relative to cellular DNA, was similar between 
EndoG-targeting and non-targeting plasmids and decreased in a time-dependent fashion. 
This result suggested that the observed effect of EndoG on plasmid stability in the 
previous experiment was not due to specific targeting of exogenous DNA by EndoG. 
Importantly, transfection of nearly-confluent cells, where cytotoxic effects of 
Lipofectamine 2000 were minimized, did not bring about a measurable response in 
EndoG expression upregulation between 24 and 48 hours post-transfection, also 
suggesting that apoptosis was not initiated via an EndoG-dependent pathway in these 
cells. Therefore, silencing of EndoG did not result in differential cell death between cells 
transfected with the EndoG-targeting and non-targeting plasmids and hence failed to 
produce the outcome observed in the previous experiment in sub-confluent HeLa cells. 
Another possible contributing factor to the observed differences in relative plasmid 
abundance per cell between EndoG-targeting and non-targeting vectors observed in sub-
confluent HeLa cells could also be differential replication of cells transfected with these 
vectors. Namely, silencing of EndoG has been reported to slow down cellular replication 
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of mammalian and other eukaryotic cells (this effect was also observed and reported in 
Chapter II of our study), but the mechanism behind this phenomenon has not been well 
described other than the observation that EndoG-deficient cells become disproportionally 
arrested in the G2/M phase of the cell cycle (Buttner et al., 2007a,b; Huang et al, 2006; 
Diener et al., 2010). This may have decreased effects of plasmid dilution by mitosis and 
could explain why relative abundance of EndoG-targeting plasmids with respect to cell 
number did not decrease between 24 and 48 hours post-transfection. 
 However, we could not demonstrate this effect experimentally using raw cell count data, 
which was similar for cells transfected with EndoG-targeting and non-targeting vectors. 
In addition, EndoG-targeting plasmids were similarly diluted with respect to cellular 
DNA as the non-targeting control plasmid at time points assayed after 48 hours post-
transfection. However, we cannot exclude this possibility as raw cell counts are not 
representative of cell viability, apoptosis status or replication potential, and the protective 
effect of EndoG-silencing with regard to cationic liposome treatment may have concealed 
replication deficiencies with respect to cells transfected with the non-targeting control 
plasmid. 
In sub-confluent HeLa cells, reporter gene (GFP) expression was higher in cells 
transfected with most of the EndoG-targeting plasmids at 24 and 48 hours post 
transfection, relative to cells transfected with the non-targeting control plasmid when 
expression was normalized with the expression of a cellular housekeeping gene. 
Although this may be an effect associated with differences in molecular integrities 
between EndoG-targeting and the non-targeting control plasmids, this cannot be 
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concluded based on the data, as quality of pDNA isolated from HeLa cells was not 
assayed.  
However, GFP expression data was normalized with plasmid DNA abundance for each 
EndoG-targeting and the non-targeting control plasmid. All EndoG-targeting plasmids 
expressed more GFP mRNA per plasmid copy relative to the non-targeting control 
plasmid at 24 hours post transfection. This would imply that EndoG-targeting plasmids 
were better preserved relative to the non-targeting control plasmid, but cannot be 
concluded with certainty as plasmid copy number does not correlate to transgene 
expression in a linear manner (Glover et al., 2010). Specifically, once a certain threshold 
of plasmid copies is reached, transgene expression remains unaffected by further 
increases (Takahashi et al., 2011). Another possible explanation for the observed effect is 
that triggering of cell death by transfection reagent cytotoxicity activated the proposed 
apoptotic RNase function of EndoG thereby reducing the amount of the GFP reporter 
gene transcript in HeLa cells that were sub-confluent at time of transfection with the 
negative control vector (Kalinowska et al., 2005). Interestingly, transfection of nearly-
confluent cells, where transfection reagent cytotoxicity was minimized, did not result in 
greater GFP mRNA expression from EndoG-targeting plasmids relative to non-targeting 
control.  
1.5 Conclusion: 
In conclusion, EndoG silencing was not found to increase exogenous DNA stability and 
transgene expression under physiological circumstances. Therefore, it is unlikely that 
EndoG is a mediator of intranuclear plasmid DNA disposition. However, protective 
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effects of EndoG silencing on exogenous DNA stability may be perceived to occur in 
cells if additional EndoG expression is induced by an extrinsic stimulus. This does not 
reflect a role for EndoG in defence against exogenous DNA, but most likely its role in 
non-specific degradation of all nuclear DNA following induction. 
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Chapter II 
 
EndoG depletion may improve efficiency of first generation adenovirus 
vector replication 
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2.1 Introduction 
The high efficiency of gene transfer into a wide variety of dividing and non-dividing 
mammalian cells, coupled with a relatively low risk of transformation, have made 
adenovirus type 5 (Ad5) derived vectors a staple tool for successful gene delivery in vitro 
and in vivo (reviewed in Yao et al., 2011). In particular, the first generation Ad5 vectors, 
which have the entire E1 region of the viral genome deleted (Ad5 ΔE1), have been used 
extensively for the transduction of therapeutic and cytotoxic genes into carcinoma cells.  
An important consideration for the use of Ad5 ΔE1 vectors is that they are considered 
replication incompetent, owing to the dependence of Ad5 on the products of E1 genes for 
the initiation of events that lead to productive viral replication (Jones and Shenk, 1979). 
However, a number of studies have demonstrated that Ad5 ΔE1 DNA is replicated in 
human tumour cells, which may be important in the context of their application in 
treatment of human malignancies (Lieber et al., 1996; Nelson and Kay, 1997; Goldsmith 
et al., 1998; Brand et al., 1999; Steinwaerder et al., 2000; Steinwaerder et al., 2001; Bernt 
et al., 2002; Ghosh and Duigou, 2005). Namely, replication of viral DNA is correlated 
with increased expression of virally encoded genes that mediate cytotoxicity (Brand et 
al., 1999; Wersto et al., 1998). Furthermore, viral DNA replication can lead to productive 
replication of the virus, which results in host cell death and the production of new virions 
with the ability to repeat this process (Steinwaerder et al., 2000; Bernt et al., 2002). 
Therefore, it is important to study factors that may enhance this process, as Ad5 ΔE1 
could potentially have oncolytic properties that may be applied for treatment of human 
malignancies. 
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2.1.1 First generation adenovirus vectors 
Several generations of Ad5 based vectors have been developed and they differ with 
respect to the sequence deletions made in the viral genome, which result in differences in 
the size of recombinant DNA they can accommodate, their immunogenicity, as well as 
their replicative potential in different cellular backgrounds (reviewed in Benihoud et al., 
1999). In the first generation Ad5 vector (Ad5 ΔE1), the early genes 1A and 1B (E1A 
and E1B) are completely deleted and usually replaced with a transgene expression 
cassette under the control of the cytomegalovirus immediate early (CMVie) 
promoter/enhancer element. The E1A encodes two major proteins, E1A 13S (or E1A-
289R) and E1A 12S (or E1A-243R), produced by differential splicing of the same 
transcription unit, which are the first viral products expressed upon wildtype Ad5 
infection (reviewed in Shenk, 1996). The E1A 13S mainly transactivates other viral 
genes, notably those encoded in the E2 and E4 regions, which are important for Ad5 
DNA replication. The major function of the E1A 12S is to drive cell cycle progression 
and to induce cellular DNA synthesis, doing so by directly transactivating cellular genes 
and by physically interacting with cell cycle regulatory proteins. In particular, the binding 
of the retinoblastoma (Rb) tumour suppressor proteins, results in the release of the E2F 
transcription factors, which in turn upregulate the expression of S phase proteins involved 
in DNA synthesis (Dyson, 1998). Therefore, quiescent cells are made to progress to S 
phase, which creates a favourable environment for viral DNA replication (Vousden, 
1995). 
In normal cells, expression of E1A gene products also triggers G1 arrest or apoptosis, 
which occurs as a result of tumour suppressor p53 stabilization (Xiong et al., 1993; 
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Miyashita and Reed, 1995). Since premature cell death would reduce viral yield, the Ad 5 
encodes two E1B proteins, the E1B 19k and 55k, which specifically attenuate p53-
mediated apoptosis and extend the time-frame available for viral replication (Rao et al., 
1992; Debbas and White, 1993). Both proteins are encoded by the same mRNA, however 
due to differentially positioned AUG translation initiation codons, they do not have 
homology in amino acid sequence (Esche et al., 1980; Bos et al., 1981; Montell et al., 
1984). The E1B 55k binds p53 directly to block it, while the E1B 19k works downstream 
of p53 in an analogous role to the Bcl-2 anti-apoptotic proteins, binding to Bax and 
preventing the release of pro-apoptotic factors from mitochondria (Sarnow et al., 1982; 
Roth et al., 1998; Han et al., 1996; Sabbatini et al., 1997). Deletion of the E1B 19k gene 
from Ad5 results in reduced viral yields with increased degradation of both cellular and 
viral DNA (Pilder et al., 1984; White et al., 1984). In addition to opposing E1A triggered 
apoptosis, the E1B 55k is important for preferential transport of late viral mRNA from 
the nucleus to the cytoplasm, a role it fulfils in co-operation with the E4 orf6 protein 
(Leppard and Shenk, 1989; Bridge and Ketner, 1990).   
In lieu of the importance of the E1 region for viral growth, Ad5 ΔE1 is considered 
replication incompetent in normal cells and can only be propagated in the permissive 
human embryonic kidney 293 (HEK293) cell line, which has been transformed with the 
adenovirus E1 region and provides its products in trans (Graham et al., 1977). However, 
transcription of late viral mRNA and synthesis of encoded late proteins, in addition to 
Ad5 DNA replication have been observed in cultured cells that have not been 
transformed with adenovirus (Brand et al., 1999). In particular, many human tumour-
derived cell lines support Ad5 ΔE1 DNA replication to various degrees, depending 
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greatly, but not exclusively, on the multiplicity of infection (MOI) (Lieber et al., 1996; 
Nelson and Kay, 1997; Goldsmith et al., 1998; Brand et al., 1999; Steinwaerder et al., 
2000; Steinwaerder et al., 2001; Bernt et al., 2002; Ghosh and Duigou, 2005). In some 
tumour cells, replication of viral DNA leads to observable cytopathic effects (CPE), 
which is a hallmark event of productive viral replication (Steinwaerder et al., 2000; 
Steinwaerder et al., 2001; Bernt et al., 2002). 
2.1.2 Replication of viral DNA in Ad5 ΔE1 infected cells 
Infection of mouse livers in vivo with Ad5 ΔE1 does not lead to de novo synthesis of viral 
DNA, which is in contrast to highly efficient viral DNA replication in isolated, cultured 
hepatocytes (Nelson and Kay, 1997). Since cells in the mouse liver are quiescent, while 
isolated hepatocytes replicate in culture, it is likely that active cell cycling is important 
for Ad5 ΔE1 DNA replication (Steinwaerder et al., 2000). As stated previously, the genes 
encoded in the E1 region are responsible for driving quiescent cells to progress through 
the cell cycle in order to make available cellular factors that are required for virus DNA 
replication and whose expression is cell cycle regulated. Since tumour cells do not need 
to be induced to progress through the cell cycle, Ad5 ΔE1 DNA replication may occur as 
a result of availability of cellular proteins and transcription factors that would otherwise 
be absent from normal quiescent cells (Steinwaerder et al., 2000; Bernt et al., 2002).  
Several cellular proteins, such as NF-IL6, heat shock proteins, and some transcription 
factors, have the ability to transactivate E1A regulated viral genes (Spergel and Chen-
Kiang, 1991; Imperiale et al., 1984; La Thangue and Rigby, 1987). In HeLa cells, which 
have been transformed with the human papilloma virus 18 (HPV-18), this function may 
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be performed by “endogenous” expression of HPV E6 and E7 genes, which bind to p53 
and pRb (Steinwaerder et al., 2001). In particular, E7 shares some homology with the 
adenovirus E1A 12S, which could lead to transactivation of Ad5 encoded viral genes 
when the E1 region is deleted (Phelps et al., 1988). However, even tumour cells that have 
not been transformed by oncogenic viruses support Ad5 ΔE1 DNA replication and the 
efficiency of this process does not correlate with the statuses of the tumour suppressors, 
p53 and pRb (Brand et al., 1999; Steinwaerder et al., 2000). Hence, the most important 
factor for efficient Ad5 ΔE1 DNA replication appears to be progression of the cell cycle 
to a favourable phase that can support both high rates of virus internalization and also 
provide cellular proteins required for viral DNA replication (Steinwaerder et al., 2000; 
Bernt et al., 2002). 
In the case of infection with wildtype Ad5, quiescent cells are made to progress to the S 
phase, however, Ad5 ΔE1 may require different cellular factors to replace the 
transactivating properties of adenovirus E1A proteins and hence require a different 
cellular environment that can provide them. This is supported by the observation that 
infection of cultured cells with Ad5 ΔE1 causes a partial G2/M arrest or delay in cell 
cycle progression, which becomes more apparent in later stages of infection, due to the 
inappropriate expression of cyclin A, cyclin B1, cyclin D and cyclin-dependent kinase 
p34cdc2 which is induced by viral E4 genes (other than orf6) (Wersto et al., 1998; Brand et 
al., 1999; Steinwaerder et al., 2000; Bernt et al., 2002). In fact, Steinwaerder et al. (2000) 
and Bernt et al. (2002) demonstrated that highest levels of Ad5 ΔE1 DNA replication 
occur in the G2/M phase and that prolongation of G2/M leads to increased efficiencies of 
Ad5 ΔE1 DNA replication in the human cervical carcinoma HeLa cells. Importantly, 
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cells artificially arrested in the G2/M phase at time of infection with Ad5 ΔE1 exhibit the 
most efficient virus internalization and viral DNA replication, relative to other points in 
the cell cycle, and exhibit MOI dependent CPE. 
2.1.3 Maximizing Ad5 ΔE1 DNA replication in tumour cells 
Endonuclease G (EndoG), a nuclear-encoded mitochondrial endonuclease, is a conserved 
apoptosis regulator in eukaryotic organisms (Diener et al., 2010). Apart from its role in 
programmed cell death, EndoG has been implicated in vital roles in the cell, including 
mitochondrial DNA replication, DNA recombination and cell proliferation (McDermott 
et al., 2011; Huang et al., 2002; Huang et al., 2006; Buttner et al., 2007a; Zan et al., 
2011). Importantly, reduction of cellular levels of EndoG by RNA interference (RNAi) 
leads to the accumulation of both yeast and mammalian cells in the G2/M phase of the 
cell cycle without any additional stimulus (Huang et al, 2006; Buttner et al., 2007a,b; 
reviewed in Galluzzi et al., 2012). Since exogenous expression of EndoG-GFP can rescue 
this phenotype, the delay in G2/M transition is a specific effect of EndoG silencing 
(Huang et al, 2006). Therefore, depletion of EndoG may prolong the G2/M delay 
associated with Ad5 ΔE1 infection of tumour cells and thus increase viral DNA 
replication in a similar manner to what has been observed when tumor cells are 
chemically arrested in the G2/M phase (Steinwaerder et al., 2000; Bernt et al., 2002). 
With respect to the application of Ad5 ΔE1 vectors for viral oncolytic therapy, 
maximizing replication of Ad5 ΔE1 DNA should enhance cytotoxicity of these vectors 
and result in higher efficacy with respect to cancer cell killing. Therefore, we tested 
whether an Ad5 ΔE1 vector which encodes an RNAi effector against EndoG expression 
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would exhibit augmented viral DNA replication and CPE in the human cervical 
carcinoma HeLa cells. 
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2.2 Materials and Methods 
2.2.1 Construction of Ad5 ΔE1 vectors 
First generation (Ad5 ΔE1) adenovirus vectors, AdsiEndoG and AdsiCAD, were 
constructed by the FLP-frt recombination system, which is based on the co-transfection 
of two plasmids with complementary viral DNA components into the E1-producing HEK 
293 cells (Ng et al., 2000; Graham et al., 1977).  
The pBHGfrtΔE1,3FLP vector (35,552bp) was a circularized human adenovirus type 5 
(Ad5) genome with the following modifications: a substitution in the viral E1 region that 
encoded the yeast site specific recombinase FLP under the control of the CMVie 
promoter/enhancer and a frt recombination sequence; a deletion of the viral E3 region; 
and a deletion of the viral packaging sequence (Ψ).  
The pDC-CG-U6-EndoGshRNA and pDC-CG-U6-CADshRNA shuttle vectors (5,354bp) 
were pUC19-based plasmids that contained Ad5 inverted terminal repeats (ITRs), Ad5 
packaging sequence, U6 promoter-regulated shRNA expression cassette (vector specific), 
CMVie promoter/enhancer-regulated AcGFP expression cassette with SV40 poly A 
signal, and a frt recombination sequence. 
Construction of pDC-CG-U6-EndoGshRNA vector has been described in Chapter I 
Materials and Methods and Results sections. This plasmid is the EndoG targeting vector 
p3. The pDC-CG-U6-CADshRNA vector was engineered in an analogous manner to 
pDC-CG-U6-EndoGshRNA (Chapter I), except the shRNA expressed by this vector 
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targeted the caspase activated DNase (CAD) mRNA at the following sequence: 
5`GAGAAGUGGACUGGGAGUA3`. 
Transfection of HEK293 cells was carried out using Lipofectamine 2000 (Invitrogen) as 
per manufacturer’s instructions. The pBHGfrtΔE1,3FLP and pDC-CG-U6-shRNA 
vectors were mixed to a final quantity of 5 µg of DNA, at equal molar ratios, and co-
transfected into nearly confluent HEK293 cells. Cultures were maintained for 10-15 days 
following transfection until visible plaques formed in the monolayer. 
Homologous recombination mediated by the site specific recombinase FLP between frt 
sequences on the pBHGfrtΔE1,3FLP and pDC-CG-U6-shRNA vectors resulted in the 
generation of Ad5 ΔE1 DNA vectors, which contained all the viral elements required for 
replication, except genes encoded in the viral E1 region. The E1 region was replaced by 
the U6 promoter-regulated shRNA expression cassette (vector specific) and a CMVie 
promoter/enhancer-regulated AcGFP expression cassette. The HEK293 cells provided the 
E1 gene products in trans facilitating production of infectious virions, detected by the 
onset of cytopathic effects (CPE). 
When ~70% of cells exhibited visible CPE, a rubber policeman was used to scrape cells 
of the surface of the culture dish. The culture medium (~2 mL) that contained infected 
cells was collected and sequentially frozen and thawed three times to release virions from 
cells that were still intact. The cell suspensions were centrifuged at 12,000g for five 
minutes to settle cell debris. The supernatant was collected and stored at -70oC. 
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A control Ad5 ΔE1 vector, AdGFP, was also used in this study, which contains the same 
CMVie promoter/enhancer regulated GFP expression cassette as AdsiEndoG and 
AdsiCAD, but is missing the U6 promoter regulated shRNA expression cassette. 
2.2.2 Confirmation of Ad5 ΔE1 vectors 
To confirm the sequences of Ad5 ΔE1 vectors, viral DNA was isolated and following 
digestion with a restriction endonuclease it was analyzed by agarose gel electrophoresis. 
In addition, PCR was used to confirm absence of wild type Ad5 contamination. 
One hundred µL of viral suspensions were mixed with an equal volume of a 1.2% SDS 
solution supplemented with 20 µL of 20 mg/mL Proteinase K. The mixtures were 
incubated at 55oC for one hour. The resulting lysates were mixed with the binding 
solution of a commercially available DNA purification kit (Norgen Biotek) and processed 
on a spin column assembly, as per manufacturer’s instructions.  
Five µL of eluted DNA was mixed with 1 µL of Hind III restriction endonuclease (NEB), 
2 µL of appropriate buffer (50 mM NaCl, 10 mM Tris-HCl, 10 mM MgCl2, 100 μg/ml 
BSA, pH 7.9) and 12 µL of DNase/RNase-free water. Reaction was incubated at 37oC for 
three hours and subsequently examined by 1% agarose gel electrophoresis. The resultant 
bands were sized by comparison to a DNA sizing ladder (Norgen Biotek). The digestion 
patterns matched with theoretical predictions based on an in silica model (Vector NTI, 
Invitrogen). 
PCR on 2 µL of eluted DNA was performed using E1 region specific primers F 
5`ATTCACGTAGCCAGCCACTC3` and R 5`TCGGTCACATCCAGCATCAC3. 
90 
 
Absence of amplification confirmed that Ad5 ΔE1 vector preps were free of 
contamination with wild type Ad5. 
2.2.3 Amplification of infectious Ad5 ΔE1 vectors 
Nearly-confluent HEK293 cells, cultured in 150 mm standard tissue culture plates were 
independently infected with AdsiEndoG, AdsiCAD and AdGFP. Infection was carried 
out by aspirating culture medium and overlaying the monolayer with the Ad5 ΔE1 vector 
of choice diluted in 2 mL of 1X PBS++ (1X PBS, supplemented with 1 mM of MgCl2 
and CaCl2). After 45 minutes of incubation in a 5% CO2-air mixture at 37oC, medium (18 
mL) was resupplied to the cells.  
When ~70% of cells exhibited visible CPE (usually 48 hours post-infection), the cells 
were scraped by a rubber policeman and the medium was collected and pooled. The cell 
suspension was centrifuged at 2000g for 10 minutes and supernatant removed. One ml of 
PBS++ was added to the cell pellet for every 150 mm dish scraped and the cells were 
resuspended by vortexing. Three cycles of freezing with liquid nitrogen and thawing at 
37oC in a water bath were sequentially carried out to lyse the cells and release virions. 
The cell suspension was centrifuged at 12,000g to pellet cellular debris and supernatant 
was collected. 
2.2.4 Determining titer of Ad5 ΔE1 vectors 
Viral titer was determined using the plaque assay standard protocol. Medium was 
aspirated from confluent HEK293 cells growing in a monolayer and cultured in 6-well 
culture dishes.  Ad5 ΔE1 vectors were serially diluted in 500 µL of PBS++ and several 
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dilutions in the expected titer range were used to infect HEK293 cells cultured in 6-well 
tissue culture dishes. After 45 minutes of incubation in a 5% CO2-air mixture at 37oC, 
PBS++ was aspirated and cells were overlaid with a liquid medium mixture of 0.6% 
UltraPureTM Agarose (Invitrogen) and MEM supplemented with 5% FBS. Plates were left 
at room temperature for 15 minutes to allow agar medium to solidify and they were 
subsequently incubated in a 5% CO2-air mixture at 37oC. Visible plaques in the cell 
monolayer developed within 5 to 10 days and were counted. Viral titer was determined 
by multiplying the visualized plaque forming units (p.f.u.) in a given well by the dilution 
factor of the initial viral suspension. 
2.2.5 Infection of HeLa cells 
HeLa cells were seeded at a density of 50,000 cells/well of a 24-well tissue culture plate 
one day before infection. On day of infection, medium was aspirated and 100 µL of 
PBS++ -diluted Ad5 ΔE1 vector was added to the monolayer. After 45 minutes of 
incubation in a 5% CO2-air mixture at 37oC, 500 µL of medium was added per well of 
cells. Next day, medium was replaced by fresh medium. 
2.2.6 DNA/RNA isolation 
Medium was aspirated and HeLa monolayers were washed twice with 1X phosphate 
buffered saline (PBS), pH7.4. A solution from a commercially available kit 
(RNA/DNA/Protein Purification Kit, Norgen Biotek) was used to lyse cells directly on 
the plate. Entire lysate was collected and applied to a purification column supplied by the 
manufacturer and recommended protocol was followed as specified. DNA and RNA were 
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eluted in separate fractions and examined for quality and quantity by agarose gel 
electrophoresis and spectrophotometry, respectively. 
2.2.7 Quantitative PCR analysis  
Quantitative PCR (qPCR) was performed with the Bio-Rad iCycler thermocycler on 3 µL 
of each DNA elution using the iQ SYBR Green Supermix (Bio-Rad) with 300 nM of 
primers specific for the E2A gene encoded on the viral vector, F 
5`ACACTCAGCGGGTTCATCAC3` and R 5`AGATGTGGCGCTACAAATGG3`. The 
human 5S gene (Fwd primer 5`GCCATACCACCCTGAACG3` and Rev primer 
5`AGCCTACAGCACCCGGTATT3`) was used for normalization and the comparative 
threshold method was used to assess the relative abundance at each time point.  The total 
reaction volume per sample was 20 µL, and the PCR protocol was as follows: 15 minutes 
at 95oC for enzyme activation, then 40 cycles of 15 seconds at 95oC, 30 seconds at 60oC 
and 45 seconds at 72oC. Melt curve analysis was performed by relative fluorescence 
assessment at 0.5oC increments with a 10 second duration, starting at 57oC and 
continuing for 80 cycles. 
2.2.8 Reverse transcription followed by qPCR 
Three µL of the total RNA elution was used in the reverse transcription (RT) reaction 
using the Superscript III system (Invitrogen). In the first step, RNA was mixed with 0.5 
µL of 100 mM oligo(dT) 18-mer primer (IDT) and the reaction volume was completed to 
10 µL using DNase/RNase free water. Denaturing at 70oC for five minutes was followed 
by cooling at 4oC for five minutes. At this step, 0.1 µL of the reverse transcriptase 
Superscript III (SSIII, Invitrogen) was added to the reaction in a mixture with 4 µL of the 
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5X First Strand Buffer, 2 µL of 0.1 M Dithiothreitol, 1 µL of 10 mM dNTPs and 2.9 µL 
of water. After the reaction mixture was completed, temperature was increased to 25oC 
for five minutes and then increased again to 42oC for 60 minutes, followed by 15 minutes 
at 70oC and an indefinite hold at 4oC.   
 
The qPCR detection of GFP transgene expression levels was carried out using the human 
β-actin gene for normalization and the comparative threshold method was used to assess 
the relative abundance of GFP mRNA at each time point. The primers used for detection 
of GFP cDNA were F 5`GATCACATGAAGCAGCACGA3` and R 5`GATGTTGCC-
ATCCTCCTTGA3` and for β-actin F 5`GCCGAGGACTTTGATTGCAC3` and R 
5`ACCAAAAGCCTTCATACATCTCA3`. The iQ SYBR Green Supermix (Bio-Rad) 
was used for the qPCR with 300 nM of primers, as described above for DNA analysis. 
Levels of EndoG mRNA were also interrogated at each time point using the primers: F 
5`GACGACACGTTCTACCTGAGCAACGT3` and R 5`CCAGGATCAGCACC-
TTGAAGAAGTG3`. The qPCR protocol for EndoG cDNA amplification varied slightly 
to protocol described previously due to the requirement of a higher primer annealing 
temperature, which was set at 65oC. 
2.2.9 Cell counting 
Medium was aspirated from HeLa cells cultured in 24-well standard tissue culture plates 
and monolayers were washed three times with 1X PBS. Cells were lifted with 200 µL of 
Gibco’s 0.05% Trypsin-EDTA (1x) and counted on the haemocytometer counting 
chamber using the Olympus CK 2 inverted microscope for magnification.  
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2.3 Results 
 
2.3.1 – Construction of recombinant Ad 5 vector for EndoG-silencing 
 
In order to test whether targeting of EndoG by RNAi would augment viral DNA 
replication in HeLa cells, we constructed AdsiEndoG, an Ad5 ΔE1 vector carrying an 
expression cassette for a shRNA directed against EndoG mRNA. In addition, a control 
Ad5 ΔE1 vector with the same backbone sequence was constructed, but encoding a 
shRNA against CAD, which is an apoptotic nuclease with no known roles outside of 
apoptosis and which is not functional in non-apoptotic cells by way of chaperone-
mediated inhibition (AdsiCAD). 
 
Figure 2.1: FLP recombinase dependent generation of subE1 Ad 5 vectors. HEK 293 
cells were co-transfected with the shuttle plasmid, pDC-CG, which encoded a cassette for 
shRNA expression and a GFP reporter gene, and with the pBHGfrtdel1,3FLP plasmid, 
which encoded the FLP recombinase as well as the entire Ad 5 sequence, without viral 
E1 and E3 genes.  
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The FLP recombinase system was employed to generate Ad5 ΔE1 vectors with 
substitutions in the E1 gene region. The pBHGfrtdel1,3FLP plasmid encoded the FLP 
recombinase as well as the entire Ad 5 sequence, without viral E1 and E3 genes, and the 
Frt recombination site. This plasmid was co-transfected with a shuttle plasmid pDC-CG-
U6-shRNA into HEK 293 cells, which have been transformed with the Ad E1 gene (Fig. 
2.1). Recombinations between the two plasmids at Frt and Ad5 ITR sites, created 
recombinant adenoviruses with the EndoG- or CAD-directed shRNA and GFP expression 
cassettes subbed in at the E1 position (Fig. 2.2).   
 
 
 
Figure 2.2: Recombinant Ad 5 vector encoding discrete shRNA and reporter gene 
expression cassettes. Recombination between the two plasmids generated a recombinant 
Ad 5 (Ad5 ΔE1) vector that encoded both the shRNA template and the GFP reporter gene 
and which replicated in HEK 293 cells producing observable cytopathic effects. 
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Since HEK 293 cells have been transformed with the E1 gene of Ad 5 and provide its 
product in trans, the recombinant viruses were allowed to replicate and produced 
observable cytopathic effects (CPE) in the cellular monolayer. The Ad5 ΔE1 vectors were 
harvested and confirmed by Hind III restriction enzyme digestion, which produced an 
expected pattern of fragment lengths when visualized on an agarose gel after 
electrophoresis (Fig. 2.3). In addition, PCR was used to confirm absence of the E1 gene 
in both Ad5 ΔE1 vectors, which ensured that the preparations were not contaminated with 
WT Ad 5 (Figure 2.4A). 
In this chapter of the study, we characterized the effects of EndoG targeting on Ad5 ΔE1 
infection in HeLa cells. However, the constructed Ad5 ΔE1 vectors were also used to test 
the effects of EndoG silencing on homologous recombination between plasmids, as well 
as transfection efficiency in Chapter III of this study. 
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Figure 2.3:  Confirmation of recombinant Ad 5 (Ad5 ΔE1) vector by Hind III restriction 
enzyme digestion. Obtained fragment lengths corresponded to the predicted pattern based 
on sequence analysis and were different than those expected for wildtype Ad 5.  
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Figure 2.4: A) The qPCR analysis of DNA isolated from AdsiEndoG, AdsiCAD and 
AdGFP using primers specific for the E1 region of the wild type Ad5 genome confirmed 
the absence of this region in all of the Ad5 ΔE1 preparations. The positive control (+ve 
control) was a plasmid that contained the entire E1 Ad5 region. The negative control 
(NTC) did not contain any template for PCR. B) The qPCR analysis of DNA isolated 
from AdsiEndoG, AdsiCAD and AdGFP using primers specific for the GFP gene 
confirmed presence of the transgene in all Ad5 ΔE1 preparations. The negative control 
(NTC), which did not contain any template sequence, did not amplify. 
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2.3.2 – Characterization of AdsiEndoG, an EndoG targeting Ad5 ΔE1 
 
2.3.2.1 Replication of AdsiEndoG DNA in HeLa cells 
 
To test whether knockdown of EndoG affects Ad5 ΔE1 DNA replication rates, HeLa cells 
were infected at MOI 10 p.f.u./cell with AdsiEndoG, an Ad5 ΔE1 encoding a shRNA 
expression cassette directed against EndoG and two control Ad5 ΔE1 vectors: AdsiCAD, 
targeting the caspase activated DNase, and AdGFP. 
 
Figure 2.5: Effect of Endog targeting on the replication efficiency of an adenovirus 
vector in HeLa cells. Relative levels of AdsiEndoG, AdsiCAD and AdGFP DNA over a 4 
day time-course in HeLa cells infected at MOI of 10 p.f.u./cell (N=3). Ad5 ΔE1 DNA 
level was inferred by qPCR analysis of the Ad5 E2A gene and normalized by the 
amplification of the cellular 5S gene, using the equation 2 (^Ct, 5S – Ct, E2A). Significant 
differences were observed at 24, 48 and 72 hours between AdsiEndoG and one or both of 
the control vectors (Student’s t test, p values <0.05). HeLa cells were seeded at a density 
of 40-50 000 cells/well prior to infection and allowed to replicate over the next four days. 
Error bars indicate SD. 
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Figure 2.5 is a summary of the relative Ad5 ΔE1 DNA levels, as assessed by qPCR, at 
five time points post-infection and normalized with the cellular 5S rRNA gene. It is 
important to note that normalizing with the 5S rRNA gene resulted in the determination 
of only approximate Ad5 ΔE1 DNA levels with respect to cell number, as differences in 
cell cycle distribution of the infected HeLa cells may have resulted in differences with 
respect to the number of 5S rRNA copies per individual cell. Nonetheless, differences in 
relative Ad5 ΔE1 DNA levels with respect to the 5S cellular gene were observed between 
AdsiEndoG and one of or both of the control Ad5 ΔE1 vectors at 24, 48 and 72 hours 
post-infection, with AdsiEndoG DNA being relatively higher compared to the control 
vectors at these time points. These results indicated enhanced AdsiEndoG DNA 
replication relative to control Ad5 ΔE1 vectors. 
To examine if the same trend was observed when normalization with cellular DNA was 
disregarded, Ad5 ΔE1 DNA levels were examined per well of infected cells rather than 
per cell. Equal proportions of total DNA elutions were analyzed by qPCR and raw Ct 
values for the E2A gene were converted to relative values based on the equation 2 -^Ct 
and the data was presented in Figure 2.6. The relative level of AdsiEndoG DNA per well 
of infected cells was statistically significantly higher than one or both of the control Ad5 
ΔE1 vectors at 24, 48, 72, and 96 hours post-infection (24, 48, and 96 hours relative to 
AdsiCAD and 24, 72, and 96 hours relative to AdGFP, t test, p values <0.05). In absolute 
terms, at the conclusion of the experiment (96 hours post-infection), there was 50 times 
more viral DNA in cells infected with AdsiEndoG, relative to its initial amount at time of 
infection, compared to only 14 and 9 times more for AdsiCAD and AdGFP, respectively. 
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Figure 2.6: Effect of Endog targeting on the replication efficiency of an adenovirus 
vector in HeLa cells disregarding normalization of data against cellular DNA. Relative 
content of AdsiEndoG, AdsiCAD and AdGFP over a four day time-course in HeLa cells 
infected at MOI of 10 p.f.u./cell (N=3). Ad5 ΔE1 DNA content was inferred by qPCR 
analysis of the Ad5 E2A gene (2 -^Ct). Significant differences were observed at 24, 48 
and 72 and 96 hours between AdsiEndoG and one or both of the control vectors 
(Student’s t test, p values <0.05). HeLa cells were seeded at a density of 40-50 000 
cells/well prior to infection and allowed to replicate over the next four days. Error bars 
indicate SD. 
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2.3.2.2 Effect of AdsiEndoG infection on HeLa cell proliferation 
 
A technical repeat of the above experiment was done in order to assess replication rates 
of infected cells over the same four day time-course (Fig. 2.7). Cells were washed with 
PBS twice and subsequently lifted by trypsinization and counted by haemocytometer. At 
each time point after the initial assessment at 6 hours post-infection, there were 
significantly fewer cells in wells infected with AdsiEndoG relative to the mock infected 
control (Student’s t test, p values <0.05). 
 
Figure 2.7: Effect of EndoG targeting on HeLa cell proliferation. Average number of 
HeLa cells infected with AdsiEndoG, AdsiCAD and AdGFP at MOI of 10 p.f.u./cell 
(N=3) or mock-infected over a four day time-course.  HeLa cells were seeded at a density 
of 40-50 000 cells/well prior to infection and allowed to replicate over the next four days. 
At each time point, cells were washed twice with PBS and lifted by trypsin. Cell counting 
was done on the haemocytometer. Error bars indicate SD. 
 
0
100000
200000
300000
400000
500000
600000
6 hours 24 hours 48 hours 72 hours 96 hours
N
u
m
b
e
r 
o
f 
H
e
La
 c
e
ll
s/
w
e
ll
Time post-infection
AdsiEndoG
AdsiCAD
AdGFP
Mock* 
* 
* 
* 
103 
 
Conversely, the only time point where the difference in cell number reached statistical 
significance between the other infection conditions, with AdsiCAD and AdGFP, and the 
mock infected control was at 96 hours post-infection. CPE was not observed in any of the 
wells at any time point after infection with all of the Ad5 ΔE1 vectors, suggesting that 
differences in cellular abundances were not a result of virus-associated lysis, but due to 
unequal cell replication rates. Therefore, targeting of EndoG resulted in a HeLa cell 
proliferation defect, which coincided with increased Ad5 ΔE1 DNA replication over the 
same time-course. 
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2.3.2.3 Infection of HeLa with AdsiEndoG at high MOI 
 
 
Since replication of Ad5 ΔE1 DNA can lead to proportional CPE when HeLa cells are 
infected at high initial MOI, we tested whether previously observed differences in Ad5 
ΔE1 DNA replication rates between AdsiEndoG and AdsiCAD or AdGFP would lead to 
differential CPE in cells infected with these vectors. Therefore, HeLa cells were infected 
at MOI of 50 p.f.u./cell, which was 5 times higher than in the initial experiment.  
 
Figure 2.8: Effect of EndoG targeting on levels of adenovirus vector-induced CPE in 
HeLa cells. Average number of adherent HeLa cells infected with AdsiEndoG, AdsiCAD 
and AdGFP at MOI of 50 p.f.u./cell (N=3) or mock-infected over a four day time-course.  
HeLa cells were seeded at a density of 40-50 000 cells/well prior to infection and allowed 
to replicate over the next four days. At each time point, cells were washed twice with 
PBS and lifted by trypsin. Cell counting was done on the haemocytometer. Error bars 
indicate SD. 
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CPE resulted in a morphological change in cell shape that lead to the detachment of cells 
from the surface of the culture dish and only adherent cells were counted at each time 
point of the experiment. At MOI of 50 p.f.u./cell, CPE was observed in all of the Ad5 
ΔE1 infection conditions, which reduced the amount of adherent cells per well compared 
to the mock infected control. The degree of observed CPE was highest in wells of HeLa 
cells infected with AdsiEndoG relative to AdsiCAD and AdGFP infected cells, which 
was reflected in the lowest adherent cell counts at 24, 48, 72 and 96 hours post-infection 
(Student’s t test p values <0.05, Fig. 2.8). At 96 hours post infection, less than 5% of cells 
infected with AdsiEndoG were still adhered to the plate, relative to mock infected 
control, compared with 24.7% and 37.2% of cells infected with AdsiCAD and AdGFP, 
respectively (Table 2.1). 
 
Table 2.1 – Percent of HeLa cells adhered to the culture dish at 48, 72, and 96 hours 
post-infection (p.i.) with AdsiEndoG, AdsiCAD and AdGFP at MOI of 50 p.f.u./cell, 
relative to mock infected control.  
Ad5 ΔE1 vector 
at MOI of 50 p.f.u./cell 
% of adherent HeLa cells relative to mock 
48 hours p.i. 72 hours p.i. 96 hours p.i. 
AdsiEndoG 37.8 18.4 4.4 
AdsiCAD 56.1 45.5 24.7 
AdGFP 67.6 56.6 37.2 
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2.3.2.4 Effect of EndoG targeting on Ad5 ΔE1-encoded transgene expression 
 
As AdsiEndoG and AdsiCAD exhibited differences in replication levels in HeLa cells 
infected at MOI of 10 p.f.u./cell, while also showing different levels of induced CPE in 
cells infected at MOI of 50 p.f.u./cell, we tested whether these differences had an effect 
on the expression of a GFP transgene both of the vectors encoded. HeLa cells were 
infected with MOI of 10 p.f.u./cell and relative GFP mRNA expression assessed (Fig. 
2.9). At 72 hours post-infection, cells infected with AdsiEndoG expressed significantly 
more GFP mRNA compared to cells infected with AdsiCAD (p value <0.05). 
 
Figure 2.9: Effect of EndoG targeting on adenovirus vector-encoded reporter gene 
mRNA expression. Relative GFP mRNA expression over a four day time-course in HeLa 
cells infected with AdsiEndoG, AdsiCAD and AdGFP at MOI of 10 p.f.u./cell (N=3). 
GFP mRNA expression was inferred by RT-qPCR analysis and normalized with the 
expression of the cellular β-actin gene using the equation 2 (^Ct, β-actin – Ct, GFP). 
Significant difference in GFP mRNA expression between AdsiEndoG and AdsiCAD was 
observed at 72 hours post-infection (Student’s t test, p values <0.05). HeLa cells were 
seeded at a density of 40-50 000 cells/well prior to infection and allowed to replicate over 
the next four days. Error bars indicate SD. 
0
1
2
3
4
5
6
7
8
6 hours 24 hours 48 hours 72 hours 96 hours
R
e
la
ti
ve
 G
FP
 m
R
N
A
 e
xp
re
ss
io
n
/c
e
ll
Time post-infection
AdsiEndoG
AdsiCAD
* 
107 
 
2.3.2.5 Knockdown of EndoG mRNA by AdsiEndoG 
 
Relative EndoG expression was also assessed by RT-qPCR in HeLa cells infected with 
AdsiEndoG, AdsiCAD and AdGFP at MOI of 10 p.f.u./cell (Fig. 2.10). At 48 hours post-
infection EndoG mRNA abundance is statistically significantly lower in cells infected 
with AdsiEndoG relative to AdsiCAD and AdGFP infected cells (p value <0.05). 
 
Figure 2.10: Effect of adenovirus vector-mediated EndoG targeting on cellular EndoG 
mRNA expression. Relative EndoG mRNA expression over a four day time-course in 
HeLa cells infected with AdsiEndoG, AdsiCAD and AdGFP at MOI of 10 p.f.u./cell 
(N=3). EndoG mRNA expression was inferred by RT-qPCR analysis and normalized the 
expression of the cellular β-actin gene using the equation 2 (^Ct, β-actin – Ct, EndoG). 
Significant differences in EndoG mRNA expression between AdsiEndoG and AdsiCAD 
and AdGFP were observed at 48 hours post-infection (Student’s t test, p values <0.05). 
HeLa cells were seeded at a density of 40-50 000 cells/well prior to infection and allowed 
to replicate over the next four days. Error bars indicate SD. 
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2.4 Discussion 
Human adenovirus type 5 derived first generation vectors (Ad5 ΔE1) are routinely used 
for the transduction of exogenous genes into human tissues and cells, both in vitro and in 
vivo (reviewed in Yao et al., 2011). Owing to the deletion/substitution of the viral E1 
region, which encodes the E1A and E1B genes, these vectors are considered replication 
incompetent in normal, quiescent cells (Jones and Shenk, 1979). However, Ad5 ΔE1 
DNA replication has been demonstrated in some proliferating, cultured cells and in 
tumour derived cells lines (Lieber et al., 1996; Nelson and Kay, 1997; Goldsmith et al., 
1998; Brand et al., 1999; Steinwaerder et al., 2000; Steinwaerder et al., 2001; Bernt et al., 
2002; Ghosh and Duigou, 2005). The efficiency of Ad5 ΔE1 DNA replication has been 
positively correlated to the development of cytopathic effects (CPE) in infected cells, and 
higher intranuclear concentration of Ad5 ΔE1 DNA is related to increased expression of 
viral genes that mediate cytotoxicity (Steinwaerder et al., 2000; Holm et al., 2004; Brand 
et al., 1999; Wersto et al., 1998; reviewed in Benihoud et al., 1999). Enhanced cell killing 
ability of Ad5 ΔE1 vectors is desired for their potential use in viral oncolytic therapy, 
therefore it is important to develop strategies that can enhance their replication in tumour 
cells (reviewed in Guse and Hemminki, 2009; reviewed in Rein et al., 2006). 
Other studies have established the importance of cell cycling for efficient Ad5 ΔE1 DNA 
replication and identified the G2/M transition in the cell cycle as the optimal cellular 
environment for this process (Wersto et al., 1998; Steinwaerder et al., 2000; Bernt et al., 
2002). Prolongation of the G2/M transition or chemically induced cell cycle arrest in this 
phase results in enhanced Ad5 ΔE1 internalization, viral DNA replication and 
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development of CPE in the cervical cancer cell line HeLa (Steinwaerder et al., 2000; 
Bernt et al., 2002).  
The mitochondrial apoptosis regulator EndoG exerts control of the cell cycle in 
physiological circumstances (Huang et al, 2006; Buttner et al., 2007; reviewed in 
Galluzzi et al., 2012). RNAi induced silencing of EndoG expression results in a cell 
proliferation defect that is characterized by an accumulation of cells in the G2/M 
transition without any additional stimuli (Huang et al, 2006). Therefore, we hypothesized 
that an Ad5 ΔE1 virus that encodes an RNAi effector against EndoG mRNA would 
exhibit augmented DNA replication and CPE in HeLa cells compared to control Ad5 ΔE1 
vectors.  
In Chapter I of this study we identified a suitable region within EndoG mRNA for 
targeting by RNAi. To facilitate the knockdown, a vector for shRNA expression was 
constructed, which also encoded an autonomous cassette for the expression of a GFP 
reporter gene. Using the FPL-frt recombination system in HEK 293 cells, we engineered 
AdsiEndoG, an Ad5 ΔE1 vector capable of knocking down EndoG levels in HeLa cells 
by RNA Pol III U6 promoter driven expression of shRNA. We also engineered the 
control vector AdsiCAD, which was homologous to AdsiEndoG, except it encoded a 
shRNA template directed against the caspase activated DNase (CAD). CAD is expressed 
in a completely inactive form in the cell and has no known functions outside of apoptosis, 
therefore its knockdown has no effect on cells under physiological circumstances. In 
addition we made use of a previously constructed Ad5 ΔE1, AdGFP, which did not code 
for any RNAi effectors, but encoded a homologous GFP expression cassette.  
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Infection of HeLa cells at MOI of 10 p.f.u./cell with AdsiEndoG and the control 
AdsiCAD and AdGFP vectors resulted in detectable viral DNA replication. This finding 
confirmed previous studies that demonstrated Ad ΔE1 DNA replication in HeLa even 
when cells are infected at a relatively low MOI (Steinwaerder et al., 2000; Bernt et al., 
2002). Furthermore, low levels of Ad ΔE1 DNA replication did not result in cell killing, 
as CPE was not observed in any of the infected cells, which was, again, an expected 
outcome based on previous reports (Steinwaerder et al., 2000; Bernt et al., 2002). 
However, the levels of Ad ΔE1 DNA replication varied significantly between cells 
infected with the AdsiEndoG and the two controls. Despite similar levels of viral DNA 
internalization, measured at 6 hours post-infection, levels of AdsiEndoG DNA were 
significantly higher relative to control vectors at 24 hours post-infection and this trend 
continued to the conclusion of the experiment. In fact, at 96 hours post-infection, 
AdsiEndoG DNA accumulated to levels that were on average 50 folds higher than the 
initial concentration used to infect cells. In comparison, over the same time-frame, the 
DNA of the two control vectors, AdsiCAD and AdGFP, increased 14 and 9 folds, 
respectively, without showing a statistically significant difference between them. 
Therefore, AdsiEndoG DNA was replicated at the highest levels, relative to the two 
control vectors. 
We hypothesized that differences in levels of Ad ΔE1 DNA replication rates between 
AdsiEndoG and the controls arose from cell cycle deregulation caused by EndoG 
depletion in AdsiEndoG infected HeLa cells. To test this claim, proliferation of HeLa 
cells infected with Ad ΔE1 or mock-infected cells was monitored over the entire course 
of the experiment. Cells infected with AdsiEndoG exhibited a cell proliferation defect, 
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unrelated to development of CPE, which was observed 24 hours following infection and 
at every time-point assayed thereafter. This finding is supported by previous reports 
which demonstrated a similar effect of EndoG knockdown on Vero, 293T and yeast cell 
proliferation, which is characterized by an accumulation of cells in the G2/M transition of 
the cell cycle (Huang et al, 2006; Buttner et al., 2007a,b). Therefore, increased rates of 
AdsiEndoG DNA replication, which coincided with a measurable decrease in EndoG 
mRNA levels and cellular proliferation, most likely resulted from a prolongation of the 
G2/M transition and, hence, the temporal extension of a favourable cellular environment 
for Ad ΔE1 DNA replication. This finding is in agreement with observations made from 
Ad ΔE1-infected HeLa cells chemically arrested at the G2/M transition phase of the cell 
cycle (Steinwaerder et al., 2000; Bernt et al., 2002). 
In contrast, HeLa cells infected with the control Ad ΔE1 vectors, AdsiCAD and AdGFP, 
did not show augmented proliferation, relative to mock-infected cells, up to 72 hours 
post-infection. However, at the very end of the experiment time-course, at 96 hours post-
infection, all of the Ad ΔE1 vectors induced a measurable cell proliferation defect, which 
was most apparent in cells infected with AdsiEndoG. This was expected since basal 
expression of viral E4 genes, other than orf6, can induce the inappropriate expression of 
cyclin A, cyclin B1, cyclin D and cyclin-dependent kinase p34cdc2 which deregulate the 
cell cycle and cause a partial arrest at the G2/M transition (Wersto et al., 1998; Brand et 
al., 1999; Steinwaerder et al., 2000).  
Since EndoG knockdown in HeLa produced a cell proliferation defect and resulted in 
enhanced replication of Ad ΔE1 DNA, we tested whether expression of the reporter gene 
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GFP, encoded by all the vectors, was similarly affected. At 72 hours post-infection, cells 
infected with AdsiEndoG expressed significantly more GFP mRNA than AdsiCAD-
infected cells. The most obvious explanation for this result is that higher concentrations 
of vector DNA and, hence, DNA template availability, led to higher transcription rates of 
the reporter gene (Bourbeau et al., 2007). Although this would explain the bulk of the 
effect, differential expression rates per vector copy could also be responsible for the 
observation. In fact, when GFP mRNA expression was normalized with cellular Ad ΔE1 
DNA content at 72 hours-post infection, cells infected with AdsiEndoG still showed 
higher reporter expression relative to AdsiCAD infected cells. A possible explanation for 
the observation may lie in the inherent property of the cytomegalovirus immediate/early 
(CMVie) promoter/enhancer element, which was used to drive GFP expression, to 
increase in activity following the activation of the cellular DNA damage response, 
especially in tumor derived cell lines (Zacal et al., 2005). In this case, knockdown of 
EndoG could have led to a higher accumulation of DNA damage, due to its proposed role 
in cellular DNA repair/recombination, which is consistent with a cell cycle arrest/delay at 
the G2/M transition (Bunz et al., 1998), and hence, higher transcription rates of a gene 
under the control of the CMVie promoter/enhancer. 
Although replication of Ad ΔE1 DNA and encoded transgene expression were enhanced 
by EndoG targeting, the question still remained whether AdsiEndoG could induce higher 
levels of CPE in the cervical cancer HeLa cells. Since, initial vector copy number is a 
predetermining factor in Ad ΔE1 DNA replication and subsequent CPE development, we 
tested whether increasing the MOI to 50 p.f.u./cell would augment the cell killing ability 
of AdsiEndoG. All of the Ad ΔE1 vectors were able to reduce HeLa cell viability at this 
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high MOI, however infection with AdsiEndoG brought on the appearance of CPE sooner 
and to a much higher extent relative to the two control Ad ΔE1 vectors. At 96 hours post-
infection, relative to the mock-infected condition, only 5% of cells infected with 
AdsiEndoG were still attached to the culture dish surface, compared to 25% and 37% of 
cells infected with AdsiCAD and AdGFP, respectively. 
These results are in agreement with the study performed by Bernt et al. (2002), which 
demonstrated synergy between Ad ΔE1 infection and administration of cytostatic drugs 
on reducing viability of HeLa cells growing in culture or a HeLa xenograft established in 
mice. Importantly, the only chemotherapeutics that showed this effect were ones that 
arrested the cell cycle at the G2/M transition, whereas G0-G1 arrest did not produce an 
effect. Therefore, increased CPE upon infection with high MOI of AdsiEndoG, observed 
in our study, is most likely a result of G2/M transition arrest or delay induced by EndoG 
knockdown. 
Another important consideration of the study performed by Bernt et al. (2002) is that 
cells were infected prior to administration of the cytostatic drugs, meaning that the virus 
was fully internalized upon drug treatment.  Therefore, the observed effects of G2/M 
arrest on enhanced tumour cell killing ability were specific to increased rates of Ad ΔE1 
DNA replication and not increased virus internalization. This is supported by our 
findings, since knockdown of EndoG, and hence the associated cell proliferation defect, 
occurred after transcription of AdsiEndoG-encoded shRNA, which required prior 
internalization of the virus. Thus, the positive effects of EndoG-knockdown on the ability 
of AdsiEndoG to induce CPE in HeLa cells were not the result of higher virus 
internalization rates, but occurred due to enhanced viral DNA replication. 
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2.5 Conclusion:  
To summarize, the data showed that EndoG knockdown induced a cell proliferation 
defect in HeLa cells, which coincided with increased replication of Ad ΔE1 DNA and 
encoded transgene expression. In addition, at high MOI, an Ad ΔE1 vector encoding 
shRNA against EndoG induced higher levels of CPE in the HeLa cervical cancer cells 
relative to traditional Ad ΔE1 vectors. Taken together, targeting of EndoG or other cell 
cycle regulators may improve the utility of first generation adenovirus vectors in cancer 
therapy. Firstly, expression of therapeutic or cytotoxic genes may be increased even upon 
infection with relatively low Ad ΔE1 doses due to increased viral DNA replication and 
second, the oncolytic ability of Ad ΔE1 may be enhanced at higher doses. 
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Chapter III 
 
EndoG depletion does not improve pDNA uptake in HeLa cells but does 
reduce levels of homologous recombination  
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3.1 Introduction 
EndoG represents the most abundant nuclease activity in humans relative to the ubiquity 
of expression across all tissues and cells, albeit at low cellular concentrations (Irvine et 
al., 2005). It has mostly been investigated in the context of programmed cell death, as its 
translocation from mitochondria to the nucleus, following apoptosis induction, coincides 
with high molecular weight DNA degradation (Li et al., 2001; Arnoult et al., 2003; Bahi 
et al., 2006; Strauss et al., 2008). Interestingly, initial studies on its role in the cell pointed 
to a vital function, specifically in mitochondrial DNA (mtDNA) replication and/or 
maintenance (Côté and Ruiz-Carrillo, 1993). Doubts surrounding the exact localization of 
EndoG within mitochondria and whether it physically interacts with mtDNA, coupled 
with absence of any apparent mtDNA-related phenotypes in EndoG-null mice, led to a 
partial dismissal of this theory. However, a recent study by McDermott et al. (2011) has 
re-established the link between EndoG and mtDNA metabolism and demonstrated that 
deregulated expression of EndoG in mice leads to phenotypic changes in the left 
ventricular mass of the heart. The dual vital and lethal roles of EndoG are reminiscent of 
another mitochondrial protein, the apoptosis inducing factor (AIF). 
Other vital functions of EndoG have also been proposed and include roles in genomic 
DNA (gDNA) recombination, as well as a role for the enzyme against uptake of foreign 
DNA (fDNA) (Buzder et al., 2009; Zan et al., 2011). Although EndoG is primarily 
localized within the mitochondrial intermembrane space, it has a putative nuclear 
localization signal at its amino end (within the same region that is cleaved off after 
mitochondrial targeting) and has been isolated from and identified by immunolocalization 
in nuclei of healthy non-apoptotic cells (Côté and Ruiz-Carrillo, 1993; Ikeda et al., 1997; 
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Huang et al., 2002; Varecha et al., 2007). Exogenous overexpression of EndoG can be 
cytotoxic, however evidence suggests that it requires other cofactors, such as other 
nucleases, and H2B phosphorylation in order to induce apoptotic DNA laddering at 
physiological concentrations (Varecha et al., 2007; Varecha et al., 2012).  
3.1.1 Role of EndoG in defence 
Uptake of fDNA by mammalian cells is restricted by cellular defence enzymes to prevent 
deleterious effects which include transformation and triggering of apoptosis (Buzder et 
al., 2009; Torchilin, 2006; Li et al., 1999; Nur et al., 2003). At the core of the defence 
network are cellular DNases which catalyze the destruction of exogenous DNA before it 
transverses the nuclear membrane (Ochiai et al., 2006a). Within the first hour after 
exogenous DNA microinjection, most of it is degraded in the cytoplasm by yet 
unidentified nucleases, which represent a major barrier to successful expression of 
encoded transgenes (Chu et al., 2006). 
Experiments in primary tubular epithelial (PTE) cells of EndoG null mice have 
implicated EndoG as one of the defence enzymes (Buzder et al., 2009). In that study, 
EndoG silencing led to increased transfection efficiency of PTE cells relative to cells with 
normal levels of this enzyme. Transfection efficiency was determined by quantifying the 
expression of a fluorescent marker gene encoded on the test pDNA vector. The observed 
positive effect of EndoG silencing on the efficiency of transfection was more pronounced 
at 48 than at 24 hours post-transfection (Buzder et al., 2009). Although vector 
degradation by nuclease activity of EndoG could explain the observed results, differential 
transgene expression between the two conditions may have occurred through other 
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silencing mechanisms, such as epigenetic changes, which do not depend on pDNA 
degradation (Hong et al., 2001). 
 Considering that successful delivery of exogenous DNA encoding therapeutic genes is at 
the core of gene therapy applications, it would be worthwhile to investigate the utility of 
EndoG knockdown for the improvement of this process. Therefore our objective was to 
knockdown expression of EndoG in the cervical carcinoma HeLa cells and then quantify 
the resultant effect on pDNA uptake. In this study, the levels of intracellular pDNA were 
measured directly by qPCR, rather than associated gene expression. Also, a human 
cervical cancer cell line, HeLa, was assayed in order to test whether the defence function 
of EndoG is conserved between species and different tissues/cells. 
3.1.2 Role of EndoG in homologous recombination 
Involvement of EndoG in recombination was first reported by Huang et al. (2002), who 
showed that it was the only enzyme isolated from HeLa cell nuclei that was able to cleave 
the herpes simplex virus 1 (HSV-1) α sequence and thereby initiate the recombinational 
event that is responsible HSV-1 genome inversion. A follow-up study by the same group 
also showed that a knockdown of EndoG in Vero cells resulted in a decrease of HSV-1 α 
sequence recombination, further implicating EndoG in this process (Huang et al, 2006). 
Recently, EndoG has been identified as one of the enzymes involved in immunoglobulin 
class switch DNA recombination (CSR) in mouse B cells (Zan et al., 2011). The action of 
EndoG to induce dsDNA breaks in switch (S) regions of the upstream and downstream 
CH genes is required for efficient CSR, as it was shown that this process is decreased two-
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fold in B cells of EndoG null mice. It is important to note that the lowered efficiency of 
CSR in EndoG null mice was not related to any changes in B cell apoptosis. 
Indirect evidence of EndoG involvement in homologous recombination comes from 
observations that decreased or attenuated expression of this enzyme results in near 
complete elimination of polyploidy in both yeasts and mammalian cells (Diener et al., 
2010; Buttner et al., 2007). Polyploidization is associated with genomic instability and is 
recognized as a precursor to aneuploidy in cancer (Buttner et al., 2007a). Survival of 
polyploidy cells is much more dependent on homologous recombination than that of 
diploid or haploid cells, as has been demonstrated by screening knockouts of genes 
involved in this process. Interestingly, deletion of NUC1, the yeast EndoG homologue 
(42% identity, 62% similarity), decreases the abundance of the polyploid phenotype from 
a starting 20% of the growing yeast population to less than 1% (Buttner et al., 2007a). 
Similarly, EndoG knockdown in both human endothelial cells and human colon cancer 
cell lines results in specific killing of tetraploid cells (Diener et al., 2010; Buttner et al., 
2007a). These observations imply that EndoG participates in genome maintenance by 
homologous recombination, however, there is not enough evidence currently for a 
definitive call. Therefore we sought to investigate the role of EndoG in homologous 
recombination using exogenous DNA substrates. 
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3.2 Materials and Methods 
3.2.1 Infection of HeLa cells 
HeLa cells were seeded at a density of 150,000 cells/well of a 24-well tissue culture plate 
one day before infection. On day of infection, medium was aspirated and 100 µL of 
PBS++ -diluted Ad5 ΔE1 vector was added to the monolayer. After 45 minutes of 
incubation in a 5% CO2-air mixture at 37oC, 500 µL of medium was added per well of 
cells. Next day, medium was replaced by fresh medium. 
3.2.2 Transfection of HeLa cells 
Two days after infection, 0.1 µg of pUC19 plasmid was mixed with Opti-MEM I 
Reduced Serum Medium without serum to a final volume of 50 µL. Next, 1 µL of 
Lipofectamine 2000 (Invitrogen) was diluted in 50 µL Opti-MEM I Reduced Serum 
Medium. The diluted plasmid was then combined with the diluted Lipofectamine 2000 
and left to incubate for 20 minutes at room temperature. The plasmid/lipofectamine 
mixture were then added to each well and mixed into the medium by gentle rocking. Six 
hours after transfection medium was changed with fresh medium. 
3.2.3 DNA isolation 
Medium was aspirated and HeLa monolayers were washed twice with 1X phosphate 
buffered saline (PBS), pH7.4. A solution from a commercially available kit 
(RNA/DNA/Protein Purification Kit, Norgen Biotek) was used to lyse cells directly on 
the plate. Entire lysate was collected and applied to a purification column supplied by the 
manufacturer and recommended protocol was followed as specified. DNA was eluted and 
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examined for quality and quantity by agarose gel electrophoresis and spectrophotometry, 
respectively. 
3.2.4 Quantitative PCR analysis  
Quantitative PCR (qPCR) was performed with the Bio-Rad iCycler thermocycler on 3 µL 
of each DNA elution using the iQ SYBR Green Supermix (Bio-Rad) with 300 nM of 
primers specific for the LacZ gene encoded on the plasmid, F 5`TAGCGGTGATGTT-
GAACTG3` and R 5`ACTATCCCGACCGCCTTACT3`. The human 5S gene (Fwd 
primer 5`GCCATACCACCCTGAACG3` and Rev primer 5`AGCCTACAGCAC-
CCGGTATT3`) was used for normalization and the comparative threshold method was 
used to assess the relative abundance of the plasmids at each time point.  The total 
reaction volume per sample was 20 µL, and the PCR protocol was as follows: 15 minutes 
at 95oC for enzyme activation, then 40 cycles of 15 seconds at 95oC, 30 seconds at 60oC 
and 45 seconds at 72oC. Melt curve analysis was performed by relative fluorescence 
assessment at 0.5oC increments with a 10 second duration, starting at 57oC and 
continuing for 80 cycles. 
3.2.5 Homologous recombination Kit 
The Homologous Recombination Assay Kit (Norgen Biotek) was used as per 
manufacturer’s instructions. Briefly, HeLa cells cultured in 24-well tissue culture plates 
were transfected with 0.5 µg of each deletion plasmid (referred to as dl1 and dl2 in the 
manufacturer’s manual) using Lipofectamine 2000, as described above. The two “dl” 
plasmids, which were based on the pUC19 cloning vector, contained non-overlapping 
deletions within the LacZ gene. Forty-eight hours after transfection, DNA was isolated 
122 
 
using a commercially available DNA isolation kit (RNA/DNA/Protein Purification Kit, 
Norgen Biotek).  
The eluted DNA was used for qPCR analysis using 2 µL of recombination-specific Assay 
Primers Mixture (proprietary sequence) in a 20 µL total reaction volume. In addition, 
same DNA was used for qPCR analysis using 2 µL of the plasmid backbone-specific 
Universal Primers Mixture (proprietary sequence) for normalization by the comparative 
threshold method. Additional normalization was performed using the human 5S gene, as 
described above. 
The qPCR protocol was as follows: 15 minutes at 95oC for enzyme activation, then 40 
cycles of 15 seconds at 95oC, 30 seconds at 58oC and 1 minute at 72oC. Melt curve 
analysis was performed by relative fluorescence assessment at 0.5oC increments with a 10 
second duration, starting at 57oC and continuing for 80 cycles. 
The expected amplicon size using the recombination-specific Assay Primers Mixture was 
420bp. 
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3.3 Results 
 
3.3.1 – Effect of EndoG silencing on plasmid DNA uptake in HeLa cells 
 
To test the effect of EndoG on fDNA uptake into mammalian cells, recombinant 
adenoviruses (Ad5 ΔE1 vectors), encoding effectors of RNAi, were used to establish 
different backgrounds in HeLa cells with respect to EndoG levels. A test plasmid 
(pUC19) was transfected into HeLa with low or wildtype EndoG expression and 
intracellular pDNA levels were assayed by quantitative PCR at 24 and 48 hours after 
transfection. 
The AdsiEndoG, an Ad5 ΔE1 recombinant adenovirus, encoded a U6 driven cassette for 
the expression of shRNA directed against EndoG mRNA, whereas AdsiCAD encoded 
shRNA directed against the caspase activated DNase (CAD), while otherwise being 
completely homologous to AdsiEndoG. Silencing CAD, another apoptotic nuclease, was 
chosen as a control condition for two reasons: first, CAD is expressed in a completely 
inactive form in the cell and is not activated unless the cell has already committed to 
caspase-dependent apoptosis; and second, unlike EndoG, CAD has not been implicated to 
participate in any biological functions that are outside of the apoptotic program. 
Therefore, silencing CAD expression should not have reduced overall nuclease activity of 
HeLa cells, as it is inactive in non-apoptotic cells, and importantly should not have 
produced any phenotypes that are not related to apoptosis.  
These Ad5 ΔE1 vectors were used to infect HeLa cells at an MOI of 10 p.f.u./cell 48 
hours prior to transfection with 0.1 µg pUC19, as previous characterization of their 
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effects on HeLa cells identified this time-point as the period were cellular abundance of 
EndoG mRNA diverged between the two conditions (Fig. 3.1). In addition, a mock 
infection was also performed using a PBS++ solution devoid of any infectious material. 
The transfection was done on confluent cells using a cationic liposome transfection 
reagent (Lipofectamine2000, Invitrogen) following the manufacturer’s recommendations.  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1: Relative EndoG mRNA levels 48 hours after infection of HeLa cells at MOI 
of 10 p.f.u./cell (N=3). Relative levels were measured by RT-qPCR and normalized with 
the expression of the human β-actin gene using the equation 2 (^Ct, β-actin – Ct, EndoG). 
EndoG mRNA levels were ~45% lower in AdsiEndoG infected cells than in cells infected 
with a control Ad5 ΔE1 vector or AdsiCAD (Student’s t test, p values <0.05). 
 
At 24 hours after transfection with 0.1 µg of pUC19, there were no statistically 
significant differences in relative pDNA abundance between AdsiEndoG and AdsiCAD 
infected HeLa cells or the mock infected control HeLa cells (Fig. 3.2). However, at 48 
hours post transfection, pDNA levels were higher in cells infected with the two Ad5 ΔE1 
125 
 
vectors relative to the mock-infected cells, reaching statistical significance (Student’s t 
test, two tailed, p values <0.05).  
 
Figure 3.2: Effect of EndoG targeting on pDNA uptake in HeLa cells. Relative levels of 
pDNA in HeLa cells infected with AdsiEndoG, AdsiCAD, or mock PBS++ solution 
(N=3). Confluent cells cultured in 24-well plates were infected at MOI of 10 p.f.u/cell 
and 48 hours later transfected with 0.1 µg of pDNA. Twenty-four and 48 hours after 
transfection, DNA was isolated and amplified using primers specific for pDNA and the 
5S gene. The pDNA levels were inferred based on ΔCt using the equation 2 (^Ct, 5S – Ct, 
pDNA). At 24 hours there are no statistically significant differences between the means 
of all three conditions (one way ANOVA, p value 0.341973). At 48 hours, after 
transfection, the relative plasmid abundances in cells infected with AdsiEndoG and 
AdsiCAD are significantly higher than in mock-infected cells (Student’s t test, 2 tailed, p 
value <0.05), but there is no significant differences between cells infected with 
AdsiEndoG and AdsiCAD (p value >0.05). 
 
To interrogate whether differential DNA degradation was the reason for the observed 
differences in pDNA levels between infection conditions at 48 hours post-transfection, 
pDNA levels were examined on a “per well” basis rather than normalized with cellular 
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DNA (Fig. 3.3). The pDNA uptake was not different when comparing between conditions 
at 24 and 48 hours post-transfection, however when comparing between the two time 
points, the only statistically significant decrease in pDNA abundance was observed for 
the mock infected control. This was not a consequence of EndoG silencing, because 
AdsiEndoG-infected cells did not show differences in pDNA uptake when compared to 
AdsiCAD-infected cells (Fig. 3.3). 
 
Figure 3.3: Effect of EndoG targeting on pDNA uptake in HeLa cells per well of 
transfected cells. Relative levels of pDNA in HeLa per well of cells infected with 
AdsiEndoG, AdsiCAD, or mock PBS++ solution (N=3). Confluent cells cultured in 24-
well plates were infected at MOI of 10 p.f.u./cell and 48 hours later transfected with 0.1 
µg of pDNA. Twenty-four and 48 hours after transfection, DNA was isolated and 
amplified using primers specific for pDNA. The pDNA levels were inferred based on 
average Ct using the equation 2 -^Ct. No differences between all conditions in plasmid 
abundance per well were observed when compared at 24 and 48 hours post transfection 
(one way ANOVA, p value > 0.05). However, the difference in pDNA abundance per 
well between 24 and 48 hours was statistically different for the mock infected condition 
(Student’s t test, 2 tailed, p value <0.05).  
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Although targeting EndoG failed to improve pDNA uptake in HeLa cells, the data left 
open the possibility that Ad5 ΔE1 infection in general may have a slight positive effect. 
To test for this, the experiment was repeated and included an additional condition where a 
control Ad5 ΔE1 (AdGFP), which does not target any endogenous mRNA, was used to 
infect HeLa cells at MOI 10 p.f.u./cell. Plasmid DNA uptake was measured at 48 hours 
post-transfection in an analogous manner to the above described method. However, there 
were no statistically significant differences in pDNA uptake between any of the 
conditions tested and Ad5 ΔE1 infection failed to improve pDNA uptake (Fig. 3.4). 
 
Figure 3.4: Effect of adenovirus infection on pDNA uptake in HeLa cells. Relative levels 
of pDNA in HeLa cells infected with AdsiEndoG, AdsiCAD, AdGFP or mock PBS++ 
solution (N=3). Confluent cells cultured in 24-well plates were infected at MOI of 10 
p.f.u/cell and 48 hours later transfected with 1 µg of pDNA. Forty-eight hours after 
transfection, DNA was isolated and amplified using primers specific for pDNA and the 
5S gene. The pDNA levels were inferred based on ΔCt using the equation 2 (^Ct, 5S – Ct, 
pDNA. At 48 hours there are no statistically significant differences between the means of 
all four conditions (one way ANOVA, p value >0.05).  
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3.3.2 – Effects of EndoG silencing on levels of homologous recomination between 
plasmids in HeLa cells  
 
EndoG has previously been implicated as a nuclease that facilitates recombination, a role 
first demonstrated for the HSV I genome. Since double stranded breaks in DNA increase 
recombination rates, the purpose of this study was to investigate whether silencing the 
nuclease EndoG would produce a measurable decrease in this process. In order to 
facilitate this experimental design, two plasmids with opposite deletions in the lacZ gene 
were co-transfected into HeLa cells with wild type or reduced EndoG levels (Fig. 3.5). 
Use of deletion plasmids has been widespread in recombination efficiency analysis, but 
mostly by interrogating expression of a gene reconstituted by homologous recombination. 
This study relied on quantification of recombination products by qPCR with primers 
designed specifically to detect the reconstituted LacZ gene. 
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Figure 3.5: Schematic representation of the homologous recombination assay. Plasmid 
vector pUC19 was modified by enzymatic digestion to produce two plasmids with partial 
deletions in the lacZ gene (pDl1 and pDl2) that can recombine to reproduce pUC19 and a 
plasmid missing two portions of the lacZ gene. Recombination events were detected by 
qPCR using recombination specific primers (depicted in blue and placed corresponding to 
their approximate binding sites) and levels of homologous recombination were 
determined by the comparative threshold method using universal primers that were 
specific for the pUC19 backbone for normalization. 
 
EndoG levels were decreased in HeLa by infection with AdsiEndoG, which targeted 
EndoG mRNA by an encoded shRNA. Control Ad5 ΔE1 vectors used were AdsiCAD 
and AdGFP. Cells were also mock infected. At 48 hours post-infection, HeLa cells were 
transfected with 0.5 µg of each deletion plasmid, since this was the time point where 
EndoG levels decreased in AdsiEndoG infected-cells (Fig. 3.1). Previous experiments by 
other groups (Wong and Capecchi, 1986; Brouillette and Chartrand, 1987) demonstrated 
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recombination between plasmids could be detected at 48 hours after co-transfection, so 
this time point was chosen for integration by qPCR (Fig. 3.5 for PCR detection method).  
 
Figure 3.6: Effect of EndoG targeting on levels of homologous recombination between 
pDNA substrates in HeLa cells. Relative levels of recombination between two LacZ 
partial-deletion plasmids in wells of HeLa cells infected at MOI 10 p.f.u. with 
AdsiEndoG, AdsiCAD, and AdGFP or mock-infected (N=3). Recombination was 
assayed by qPCR 48 hours post co-transfection using primers specific for a fully 
reconstituted LacZ gene and normalized with total plasmid abundance inferred by 
universal primers specific for all plasmid variants using the equation 2 (^Ct, universal – 
Ct, recombination). Recombination levels were significantly lower in AdsiEndoG 
infected HeLa cells compared with AdGFP infected or mock infected cells (Student’s t 
test, p values <0.05).  
 
Recombination rates for all conditions are summarized in Figure 3.6. Recombination 
levels were lowest in wells where HeLa cells were infected with AdsiEndoG, and this 
was statistically significant relative to wells of cells infected with AdGFP or mock-
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infected. Recombination rates were also normalized with cellular DNA, by interrogating 
the 5S cellular gene, to determine relative per cell recombination (Fig. 3.7). Although 
recombination levels were still significantly lower in AdsiEndoG infected cells compared 
to AdGFP infected cells (p value <0.05), the difference relative to mock infected cells, 
just failed to reach statistical significance (p value 0.07). 
 
Figure 3.7: Effect of EndoG targeting on levels of homologous recombination between 
pDNA substrates in HeLa cells normalized against cellular DNA. Relative levels of 
recombination between two LacZ partial-deletion plasmids normalized with the cellular 
5S rRNA gene (N=3). All cells were infected at MOI 10 p.f.u. with AdsiEndoG, 
AdsiCAD, and AdGFP or mock-infected. Recombination was assayed by qPCR 48 hours 
post co-transfection using primers specific for a fully reconstituted LacZ gene and 
normalized with total plasmid abundance inferred by primers specific for all plasmid 
variants (Fig. 5). Further normalization with the cellular 5S gene was performed to 
determine relative levels of recombination per cell using the equation 2 [^Ct, 5S – (Ct, 
universal – Ct, recombination)]. Recombination levels were significantly lower in 
AdsiEndoG infected HeLa cells compared to AdGFP infected cells (Student’s t test, p 
values <0.05).  
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The PCR products of the amplification generated by recombination assay primers were 
also examined by gel electrophoresis. This was done to determine if the generated 
plasmids reconstituted the LacZ gene by homologous recombination, in which case the 
expected amplicon size was 420bp. Amplicons that were not of this size could potentially 
be generated by non-homologous recombination, such as non-homologous end-joining 
following double stranded breaks in the two LacZ deletion plasmids or due to non-
specificity. 
 
 
 
Figure 3.8: Detection of recombination specific PCR products. Gel electrophoresis (1% 
agarose gel) of PCR products facilitated by amplification of isolated DNA samples using 
assay primers specific for recombination between two LacZ deletion plasmids. Expected 
amplicon size was 420 bps for homologous recombination products. DNA was isolated 
from HeLa cells infected with AdsiEndoG, AdsiCAD, AdGFP or mock infected (MOI 10 
p.f.u./cell) and co-transfected with two deletion plasmids (0.5 µg each). Two of the 
samples infected with AdsiEndoG showed non-specific amplification (~200 bps). This 
was also observed for one sample from AdsiCAD and Ad GFP infected cells. NTC 
denotes no template control. 
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From Figure 3.8, it was apparent that PCR interrogation of some samples produced 
amplicons that were not of the expected size (420 bps) for homologous recombination-
generated templates. Specifically, two samples from AdsiEndoG infected cells and one 
from each other AdsiCAD and AdGFP infected cells. These could be products generated 
from templates that recombined in a non-homologous fashion, or non-specific 
amplification. Interestingly, the two samples with the highest amount of the non-specific 
product from cells that were infected with the AdsiEndoG, correspond directly to the two 
samples which showed the least amount of homologous recombination interrogated by 
quantitative PCR. 
Since mock infected cells did not show this non-specific product, we analyzed whether 
Ad5 ΔE1 infection alone or in combination with transfection with either of the deletion 
plasmids (but not together) would result in non-specific amplification. However, none of 
the samples were amplified as none of the qPCRs reached threshold (data not shown) 
when recombination specific primers were used. However, all of the samples were 
amplified when universal primers were used, confirming that pDNA was isolated. 
To summarize, targeting of EndoG by shRNA expressing Ad5 ΔE1, AdsiEndoG, reduced 
levels of detectable homologous recombination in HeLa cells between two deletion 
plasmids compared to a control Ad5 ΔE1 vector, Ad GFP.  
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3.4 Discussion 
3.4.1 EndoG is not a cellular defence enzyme against pDNA uptake in HeLa cells 
Successful uptake of exogenous DNA, such as pDNA, by mammalian cells is restricted 
by a number of cellular enzymes in order to prevent associated deleterious effects 
(Buzder et al., 2009). These include transformation or cell death by triggering apoptosis 
(Torchilin, 2006; Li et al., 1999; Nur et al., 2003). The greatest barrier for exogenous 
gene expression is the degradation of vectors by yet unidentified cellular nucleases (Chu 
et al., 2006). A recent report by Buzder et al. (2009) identified the level of nuclease 
activity of EndoG, a mitochondrial apoptosis regulator, as a determining factor in the 
efficiency of pDNA uptake of TKPTS and mouse PTE cells. Specifically, uptake of 
pDNA was enhanced by EndoG knockdown as measured by the level of expression of 
fluorescent reporter gene encoded on the vector. The observed effect was greater when 
measured at 48 hours post transfection, relative to 24 hours post-transfection. 
In order to determine whether EndoG performs a similar function in human tumour cells, 
due to potential therapeutic implications, we tested the effect of EndoG knockdown on 
pDNA uptake in the cervical carcinoma cell line HeLa. To facilitate EndoG knockdown 
in HeLa, we made use of the previously constructed AdsiEndoG (Chapter II), a first 
generation adenovirus vector (Ad5 ΔE1) that encoded a cassette for the expression of 
shRNA directed against EndoG mRNA. Subsequently, HeLa cells were transfected with a 
test plasmid (pUC19) and the efficiency of the uptake was measured by quantitative PCR 
(qPCR).  
135 
 
EndoG knockdown in HeLa did not improve uptake of pDNA, assayed at 24 and 48 
hours post-transfection, suggesting that EndoG is not a limiting factor for successful 
uptake of exogenous DNA. This result was not surprising considering the cellular 
localization of EndoG and its proposed roles in the cell.  
Once pDNA transverses the cellular membrane and is released from endosomes, the bulk 
of vector degradation occurs in the cytoplasm, during intracellular trafficking to the 
nucleus (Chu et al., 2006). Therefore, cytoplasmic nucleases are the major effectors of 
pDNA degradation. Considering that the main cellular localization of EndoG is in the 
mitochondrial intermembrane space along with smaller concentrations in the nucleus, it is 
unlikely that EndoG is a mediator of cytoplasmic pDNA degradation (McDermott et al., 
2011). However, upregulation of EndoG expression, due to extrinsic stimuli, may 
increase cytoplasmic EndoG levels (Varecha et al., 2007), which could in theory reduce 
pDNA uptake by the non-specific nuclease action of EndoG on vector substrates. In 
addition, apoptotic stimuli may induce both the upregulation and the translocation of high 
quantities of EndoG to the nucleus, where its nuclease action would non-specifically 
cleave chromatin and exogenous DNA substrates (Li et al., 2004; Zhao et al., 2009; 
Zhang et al., 2009; Lee et al., 2008; Mercer et al., 2010; Papa and Germain, 2011; 
Apostolov et al., 2011; Wu et al., 2010; Mitra et al., 2012; Ho et al., 2009; Yeh et al., 
2011). 
Another factor that could explain the contradictory results of this study in relation to 
those of Buzder et al. (2009) is the difference in cellular backgrounds used to evaluate 
EndoG activity on pDNA uptake. Although EndoG is ubiquitously expressed in 
mammalian cells, the levels of expression between tissues and cell lines can vary 
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considerably, which could determine the roles EndoG performs in the cell (Prats et al., 
1997). This effect has been observed in relation to apoptosis phenotypes with other 
nucleases, such as the caspase activated DNase (CAD) and DNase γ in neuronal 
apoptosis, where differentiation-influenced expression levels of each nuclease determine 
which of the two enzymes catalyzes low molecular weight DNA degradation in response 
to apoptotic stimuli (Shiokawa and Tanuma, 2004). 
Furthermore, experimental conditions also may have contributed to the discrepancy 
between the results. In this study, near-confluent HeLa cells were transfected using a 
cationic liposome transfection reagent (Lipofectamine2000, Invitrogen), which is 
inherently cytotoxic and induces apoptosis via the mitochondrial pathway due to an 
increase of intracellular reactive oxygen species (ROS) (Kongkaneramit et al., 2008; 
Takano et al., 2003; Aramaki et al., 2000; Aramaki et al., 1999; Iwaoka et al., 2006; 
Takano et al., 2001). In Chapter I of this study we have shown that Lipofectamine2000-
mediated transfection of cells seeded at low initial density induced EndoG expression and 
may have contributed to increased pDNA vector degradation, which was absent in cells 
that were seeded at near-confluence at time of transfection. Degradation of pDNA most 
likely occurred due to induction of apoptosis which resulted in non-specific degradation 
of all intranuclear DNA, regardless of origin. Importantly, results from Chapter I showed 
that EndoG knockdown had a perceived positive effect on plasmid stability in sub-
confluent HeLa cells, possibly by attenuating apoptosis in transfected cells. This is 
supported by other studies that demonstrated the protective effect of EndoG silencing 
upon treatment of cells with various apoptotic inducers (Li et al., 2004; Wang et al., 
2008; Basnakian et al., 2006). 
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In the study performed by Buzder et al. (2009) Lipofectamine2000 was also used to 
transfect pDNA into TKPTS and mouse PTE cells. Although this cannot be stated with 
certainty, it is possible that part of the observed positive effect on pDNA uptake in 
EndoG deficient cells could have occurred due to an abrogated response to increased 
intracellular ROS. In their experimental design, Buzder et al. (2009) used the percentage 
of cells expressing the CFP fluorescent marker, which is encoded by the test pDNA 
vector, as measure of transfection efficiency. This could have contributed to the observed 
effect of EndoG knockdown on pDNA uptake, as cells that expressed wild type levels of 
EndoG could have underwent ROS induced apoptosis, thereby reducing the number of 
CFP expressing cells. In contrast, higher survival rates of EndoG depleted cells upon 
transfection could have produced a perceived positive effect on transfection efficiency. 
However, we are cautious in making this conclusion as the previously stated factors may 
be responsible for the discrepancy between our results and they may not be related to 
apoptosis or the cytotoxicity of the cationic liposome transfection reagent. 
 
3.4.2 Knockdown of EndoG decreases homologous recombination between plasmids in 
HeLa cells  
EndoG is primarily localized in the mitochondrial intermembrane space (IMS), however 
it is also found in the nucleus, albeit at much lower levels (Côté and Ruiz-Carrillo, 1993; 
Ikeda et al., 1997; Huang et al., 2002). To initiate high-scale chromatin degradation 
associated with apoptosis, EndoG requires a concentrated translocation from the 
mitochondrial IMS to the nucleus, in addition to H2B phosphorylation and possibly the 
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co-operation of other nucleases, such as DNase I, topoisomerase II and apoptosis 
inducing factor (AIF) (Zhang et al., 2007; Widlak et al. 2001, Buttner et al., 2007b; 
Varecha et al., 2012). Importantly, the nuclear concentration of EndoG in physiological 
circumstances may be important for DNA repair and recombination (Huang et al., 2006; 
Buttner et al., 2007a). 
The first evidence for the role of EndoG in DNA recombination came from studies on 
herpes simplex type I (HSV I) replication (Huang et al., 2002). The characteristic 
inversion of the viral genome is dependent on alpha (α) sequence-mediated 
recombination, which is initiated by double stranded breaks in GC rich tracts within the 
sequence. The only enzyme isolated from HeLa cell nuclei capable of initiating HSV I 
recombination is EndoG, and furthermore, knockdown of EndoG in Vero cells resulted in 
decreased α sequence-mediated recombination (Huang et al., 2002; Huang et al., 2006). 
In addition, EndoG knockout mice exhibit reduced B cell immunoglobulin class switch 
DNA recombination, suggesting that EndoG is required for the generation of double 
stranded breaks in switch regions (Zan et al., 2011).  
To investigate a potential role for EndoG in homologous recombination between 
exogenous DNA substrates, we co-transfected two pUC19-derived plasmids with non-
overalpping deletions in the LacZ gene into HeLa cells with normal or reduced EndoG 
levels. Reconstitution of the LacZ gene, as measured by a very sensitive PCR-based 
approach, was used as a marker for successful homologous recombination. 
Levels of homologous recombination between the two deletion plasmids were low 
(~0.01%) in HeLa cells, regardless of EndoG status.  This was expected based on other 
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studies which reported low efficiencies of recombination between non-linearized 
extrachromosomal DNA substrates in mammalian cells (Wong and Capecchi, 1986; 
Brouillette and Chartrand, 1987). Furthermore, non-homologous recombination, 
exemplified by non-homologous end-joining, is a competing mechanism of DNA 
recombination and may reduce homologous recombination (Anderson and Eliason, 1986; 
Brouillette and Chartrand, 1987; Seidman, 1987; Zaunbrecher et al., 2008; reviewed in 
Hastings et al., 2009). Nonetheless, we were able to detect specific homologous 
recombination products in transfected cells, and our results showed that EndoG 
knockdown reduced levels of HR between two pDNA substrates in HeLa cells.  
In Chapter I of this study, we confirmed previously reported activity of EndoG on a 
pDNA substrate in a standard EndoG activity assay using HeLa cell extracts. Although 
EndoG is an enzyme which preferentially introduces single stranded nicks in dsDNA, it is 
quite capable of degrading pDNA fully when those nicks accumulate on opposite strands 
of the DNA duplex and result in a double stranded break (Widlak et al., 2001). This is 
important in the context of its ability to initiate DNA recombination events, as double 
stranded break repair is a major driving force for homologous recombination (Dellaire et 
al., 2002; reviewed in Hastings et al., 2009).  
Generation of double stranded breaks in cellular DNA occurs as a result of extrinsic 
stress, endonuclease activity or during normal cellular processes, such as DNA 
replication (reviewed in Hastings et al., 2009). Repair of double stranded breaks is 
facilitated in a large part by homologous recombination to ensure sequence fidelity and 
prevent deleterious chromosomal rearrangements. Although pDNA is extrachromosmal, 
it is nonetheless a suitable substrate for cellular DNA repair proteins (Dellaire et al., 
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2002). Considering a common DNA repair model, once double stranded breaks are 
detected, cellular exonucleases mediate 5  ` end resection to generate long stretches of 
single stranded DNA with free 3` OH groups (reviewed in Hastings et al., 2009). The 
cellular DNA repair protein Rad51 guides single strand invasion into a homologous 
region of another DNA molecule. Extensive homology is required between 
recombination partners, which was facilitated by the design of the deletion plasmids used 
in our study (Ayares et al., 1986). Following the extension of the 3` OH of the invading 
strand and second end incorporation, crossing over can occur depending on how the 
double Holiday structure is resolved (reviewed in Hastings et al., 2009), resulting in the 
reconstitution of the LacZ gene. Therefore, it is likely that the negative effects of EndoG 
knockdown with respect to HR are a result of decreased nuclease activity available to 
generate double stranded breaks in homologous recombination substrates. 
The results of this chapter are indirectly supported by those from Chapter II of this study, 
which demonstrated a cell proliferation defect in HeLa cells following EndoG 
knockdown. Other studies have also reported that depletion of EndoG leads to an 
accumulation of mammalian and yeast cells in the G2/M transition of the cell cycle, 
which is usually associated with an increase in unresolved DNA damage (Huang et al, 
2006; Buttner et al., 2007a,b; Bunz et al., 1998). Since homologous recombination is a 
DNA damage repair pathway it is conceivable that absence of EndoG leads to a defect in 
this process. Furthermore, maintenance of polyploidy requires efficient homologous 
recombination, presumably to deal with the increased burden of DNA damage associated 
with a larger genome, and it may be telling that EndoG knockdown almost completely 
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eradicates this phenotype from mammalian and yeast cells growing in culture (Diener et 
al., 2010; Buttner et al., 2007a). 
3.5 Conclusion: 
In summary, the data presented in this chapter show that EndoG knockdown did not 
improve pDNA uptake in HeLa cells, making it an unlikely target for enhanced 
delivery/expression of therapeutic genes into tumour cells. However, the data show a 
small but statistically significant reduction in homologous recombination between 
exogenous DNA in HeLa cells following EndoG knockdown, implying a role for EndoG 
in this process. 
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Overall Conclusions of the Study 
Using the gene knockdown approach, we studied the role of EndoG in the cervical cancer 
cell line HeLa, with a particular focus on its interaction with exogenous DNA due to 
potential considerations for gene therapy efforts. The results generated by this study 
demonstrated that EndoG knockdown in HeLa cells does not improve fDNA uptake, but 
may positively affect its short-term stability and encoded transgene expression in certain 
non-physiological circumstances that induce additional EndoG expression. These 
observations make it unlikely that EndoG has a universal defence role against the uptake 
and maintenance of fDNA. However, future experiments should be performed in other 
tumour and non-tumour cell lines before EndoG can be definitively dismissed as a 
defence DNase and a target for successful gene therapy. EndoG knockdown did induce a 
measurable HeLa cell proliferation defect, which supports previous claims that EndoG 
exerts control over the cell cycle. This effect coincided with enhanced DNA replication 
and encoded transgene expression of a first generation adenovirus vector in HeLa cells, 
most likely as a result of a prolongation of a favourable cellular environment for viral 
DNA replication. This finding may have potential implications for the use of first 
generation adenovirus vectors for viral oncolytic therapy, as EndoG targeting markedly 
improved their cytotoxicity when they were applied at higher concentrations. Utility of 
EndoG knockdown for adenovirus vector-mediated therapy of human malignancies 
should be further tested in other tumour cells to determine if the beneficial effects 
observed in HeLa cells are universal. Finally, knockdown of EndoG reduced homologous 
recombination between plasmid DNA substrates in HeLa cells. This finding demonstrated 
that the previously reported role of EndoG in homologous recombination of cellular DNA 
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also extends to exogenous DNA substrates. In conclusion, the results of this study are 
significant and relevant for the fields of gene therapy and virus oncolytic research. 
Continued work on the interaction of EndoG and adenovirus vectors, in particular, should 
be undertaken considering the promising initial results reported here, which may be of 
use for treatment of human carcinomas. 
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